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ABSTRACT OF THE DISSERTATION 
 
Understanding Clinician Decision-Making  
Around Opioid Prescribing 
 
 
by  
 
 
Michelle Sophie Keller 
Doctor of Philosophy in Health Policy and Management 
University of California, Los Angeles, 2019 
Professor Jack Needleman, Co-Chair 
Professor MarySue Heilemann, Co-Chair 
 
This dissertation examines how clinicians are making decisions about prescribing opioids in 
the midst of a public health crisis. In the first paper, I used a qualitative study design to understand 
how, why, and when clinicians use risk mitigation strategies when prescribing opioids. For three risk 
mitigation strategies – the opioid agreement, urine drug testing, and risk screening checklists – I 
identified two groups of clinicians: Adopters, who found them useful and valuable and Non-
adopters, who found them awkward and disruptive. In the second paper, I examined how clinicians 
made decisions about assuming new patients’ existing opioid prescriptions and identified three 
approaches: the Staunch Opposers, who were highly averse to continuing opioid prescriptions for new 
patients; the Cautious and Conflicted Clincians, who felt uneasy about prescribing opioids, but were 
willing to manage new patients’ prescriptions if the patient was perceived as trustworthy and if the 
dose and medication type fell within their comfort zone; and the Rapport Builders, who were the most 
willing to assume a new patient’s opioid prescription, even if the prescription was for a high dose. In 
the third study, I examined a sample of visits of patients seen by primary care clinicians for low back 
   iii 
pain from 2013-2017 and analyzed whether receipt of an opioid prescription was associated with 
comorbidities that would indicate the prescription was potentially appropriate or inappropriate. I 
found that visits for which patients had selected NSAID contraindications, including kidney disease 
and concurrent or long-term use of anticoagulants or antiplatelet medications, had higher odds of 
the receipt of an opioid prescription, reflecting potentially appropriate prescribing. However, visits 
where patients had relative contraindications for opioids, such as concurrent benzodiazepine 
prescriptions or a history of substance use disorder, had significantly elevated odds of opioid receipt, 
reflecting potentially inappropriate prescribing. Findings from this dissertation expand and extend a 
conceptual model for decision-making around prescribing. I identified several new constructs that 
may influence prescribing, including (1) the nature of the patient-clinician relationship, (2) the 
management of risks to both the patient and clinician, (3) ethical considerations, and (4) the 
prescriber’s identity and role as a clinician.  
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CHAPTER 1: INTRODUCTION 
 
The prescription opioid epidemic has evolved significantly since its inception in the 1990s. 
First-time prescriptions have decreased steadily since 2012 (1), and the overall rate of prescriptions 
per 100 persons has also declined in recent years (2). The proportion of high-dose and long-duration 
opioid prescriptions has also decreased in the past decade (1, 2). Since 2012, there has also been an 
important reduction in the percentage of clinicians initiating opioid therapy in patients not currently 
on opioids (1). Additionally, overdose deaths associated with prescription opioids have plateaued 
over the last five years (3).  Yet the news is not all positive. Since 2013, a new wave of drug overdose 
death rates has begun, with illicit fentanyl driving up deaths dramatically (3). While the overall rate of 
prescriptions has declined, individuals who were started on prescription opioids in previous years 
when prescribing was more liberal have continued receiving prescriptions and many are now chronic 
opioid users (2). Individuals who started taking opioids for acute or chronic pain may now have 
developed substance use disorder or developed long-term opioid use. Substance use disorder can 
begin with a legitimate prescription: four in five new heroin users start by misusing prescription 
opioids (4). 
Policies and guidance related to opioid prescribing continue to evolve as well. In 2016, in 
response to the opioid epidemic, the Centers for Disease Control and Prevention (CDC) issued 
guidelines for opioid prescribing (5). The CDC guidelines included recommendations that clinicians 
assess risks and benefits of opioids for each patient, evaluate opioid-related harms, reduce higher 
doses, and prescribe shorter courses of opioids. States responded both to the guidelines and the 
opioid epidemic with an onslaught of new legislation, requiring providers to check state databases of 
controlled substances, imposing limits on first-time prescriptions, and requiring the prescription of 
naloxone to any patient on chronic opioid therapy (6). While well intentioned, policies and 
guidelines developed in response to the opioid epidemic may be having unintended consequences. A 
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2019 report detailing the findings of a multidisciplinary panel of experts identified a variety of 
challenges associated with implementing the 2016 CDC guidelines. The panel identified that recent 
policies could be leading prescribers to cease prescribing opioids, limit doses without considering 
individual patient needs, begin involuntary opioid tapers, and enforce inflexible prescription duration 
limits (5, 7). In an April 2019 commentary in the New England Journal of Medicine, the CDC guideline 
authors also noted how recent policies may have gone beyond the original guidelines (8). Given the 
risks of prescription opioids and the current public health crisis of prescription opioid overdoses, 
decision-making around opioid prescribing has become increasingly complex and is not well 
understood. As the CDC guideline authors wrote in their 2019 perspective: “We need better 
evidence in order to evaluate the benefits and harms of clinical decisions regarding opioid 
prescribing” (8).  
Thus, this dissertation aims to examine how clinicians are making decisions about 
prescribing opioids in this fraught and evolving environment. In the first paper, I use a qualitative 
study design and constructive grounded theory methodology to examine how and why clinicians use 
risk mitigation strategies recommended by the 2016 CDC guidelines such as opioid agreements, 
urine drug testing, and risk assessment checklists. I explore why certain clinicians are hesitant to use 
the strategies while others have eagerly adopted them. In the second paper, I also use a qualitative 
research design and explore how clinicians make decisions about assuming new patients’ existing 
opioid prescriptions. This study touches upon concerns articulated by the authors of the CDC 
guidelines in their recent NEJM commentary regarding whether clinicians may be refusing to 
prescribe opioids or manage patients already on long-term opioid therapy. In the third study, I 
examine a sample of visits of patients seen by primary care clinicians for low back pain from 2013-
2017 and analyze whether receipt of an opioid prescription is associated with comorbidities that 
would indicate the prescription is potentially appropriate or inappropriate. Specifically, I analyze 
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whether patients with contraindications for NSAIDs are more likely to receive an opioid 
prescription. I also examine whether patients with relative contraindications for opioids are less 
likely to receive an opioid prescription.  
Together, these papers demonstrate how clinicians are grappling with the various decisions 
surrounding opioid prescribing in this difficult era, including how and whether they assess risk of 
misuse or abuse, whether to assume a new patient’s existing opioid prescriptions, and how to decide 
whether an opioid prescription might be appropriate based on a patient’s comorbidities and 
prescriptions. The findings can inform policies at the health system and regulatory levels, aiding 
administrators and policymakers with balancing the risks and harms of opioids with the 
consequences of these policies for patients and clinicians.  
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CHAPTER 2: Study 1 : How do clinicians of different specialties perceive and use opioid 
risk mitigation strategies? A qualitative study 
 
ABSTRACT 
 
Background: In response to the opioid epidemic, states and health systems are encouraging 
clinicians to employ four risk mitigation strategies: opioid agreements, state-based prescription 
database management programs, urine drug tests, and screening checklists. These strategies are 
aimed at assessing a patient’s risk for opioid misuse or abuse. The objective of this study was to 
understand how clinicians perceived and used different opioid risk mitigation strategies and to 
identify barriers to their implementation.  
Methods: We used constructivist grounded theory methodology to guide study design and 
qualitative analysis. We conducted interviews with clinicians in multiple specialties about their 
perceptions and use of the four risk mitigation strategies from 2016-2018. Clinicians were affiliated 
with one academic medical center.  
Results: Our sample included 32 clinicians of different specialties who prescribe opioid medications 
in the outpatient setting, including 21 primary care physicians (17 internal medicine physicians, three 
family medicine physicians, and one primary care nurse practitioner), 6 clinicians with specialized 
training in pain (three anesthesiologists, two dentists with additional training in pain medicine, and 
one physical medicine and rehabilitation physician), and 6 other specialists (four rheumatologists and 
two neurologists). Some internists and family practice physicians had both primary care practices 
and worked in the urgent care setting. Most clinicians used the state-based prescription database 
program to check on patients’ previous prescriptions. For the other three risk mitigation strategies – 
the opioid agreement, urine drug testing, and risk screening checklists – we identified two 
approaches: Adopters, who found them useful and valuable and the Non-adopters, who found them 
awkward and disruptive. Adopters were primarily clinicians who typically see patients episodically: 
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pain specialists and urgent care clinicians. Adopters found strategies helpful in reducing the need to 
rely on gut feelings, setting limits with patients, and having objective evidence of misuse or abuse. 
Clear protocols on when and how to use the strategies also facilitated their use. Non-adopters were 
largely primary care and rheumatologists, clinicians who often have long-term relationships with 
patients. Non-adopters perceived the strategies as interfering with the clinician-patient relationship, 
superfluous given their existing patient relationships, or unfair to patients. Non-adopters in the 
primary care setting also cited lack of time and resources to successfully implement the strategies. 
Conclusions: In settings where long-term relationships are important and valued, such as primary 
care and rheumatology, clinicians were less likely to use risk mitigation strategies perceived as 
disruptive to the patient-clinician relationship. In settings where care is episodic, such as urgent care 
and pain medicine, clinicians were more likely to embrace the risk assessment strategies, as they 
helped clinicians set limits and use objective evidence to document misuse or abuse. Risk mitigation 
strategies tailored to different settings may improve adoption and use.  
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INTRODUCTION 
Identifying misuse and abuse of prescription opioids is important for the prevention of 
substance use disorders and drug overdoses (1, 2). Four in five new heroin users start by misusing 
prescription opioids (3) and misuse of opioids can lead to accidental overdose or death (4). In 2016, 
of the 63,632 deaths from drug overdose, 66.4% involved opioids, including prescription and illicit 
opioids (5). The opioid crisis has prompted federal agencies, state policymakers, and physician 
societies to promote four major strategies to identify individuals at high risk for opioid misuse or 
addiction (1, 2, 6). Risk mitigation strategies include opioid agreements, state Prescription Database 
Management Programs (PDMPs), urine toxicology testing, and risk assessment tools. Opioid 
agreements, sometimes referred to as pain agreements or opioid contracts, are documents listing 
conditions to which patients must agree in order to receive opioid prescriptions. These conditions 
can include random urine drug tests, pill counts, and the use of only one prescriber and pharmacist. 
PDMPs are state-based databases documenting the prescription and dispensation of controlled 
substances that can be accessed by clinicians and pharmacists. These databases can assist clinicians 
and pharmacies in identifying individuals receiving large quantities of opioids from multiple sources 
(7). Urine toxicology tests are used to detect whether the patient is taking prescription opioids as 
indicated and/or to screen for the use of illicit drugs such as cocaine or methamphetamines (8). Risk 
assessment checklists include the Opioid Risk Tool and other checklists aimed at estimating a 
patient’s risk for misuse or abuse (9).  
The evidence on whether these risk mitigation strategies are effective in ultimately decreasing 
patients’ risk of misuse, addiction, or overdose is limited and often mixed. A systematic review 
found limited evidence that opioid agreements and urine drug tests reduce opioid misuse (10). 
Despite limited evidence of their effectiveness, federal agencies, states, physician societies, and 
health organizations are promoting the use of these strategies, building them into quality 
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improvement measures and state legislation (2, 6, 10-14). In Table 1, we summarize the various risk 
mitigation strategies, the known evidence base, and available information on their use and 
implementation. Given the widespread efforts to implement these strategies, understanding 
perceptions about them and their on-the-ground use can inform efforts to improve their 
effectiveness and use. 
Previous studies have analyzed the use of these risk mitigation strategies independently, 
examining the use of PDMPs, opioid agreements, or urine drug tests in the emergency department 
and primary care settings (15-19); however, less is known about how clinicians use these strategies 
collectively, substituting or favoring one risk mitigation strategy for another. Moreover, the majority 
of studies have focused on the use of these strategies in the primary care and emergency department 
settings; very few have examined their use in outpatient anesthesiology, neurology, and 
rheumatology clinics. Comparing and contrasting how clinicians who prescribe opioids in different 
settings and specialties use these strategies can provide insights into common barriers to their use 
and highlight areas where implementation and use has been most effective.  
The objective of this study was to examine perceptions and use of these four risk mitigation 
strategies among a sample of clinicians affiliated with one academic medical center in a large 
metropolitan area. We analyzed use of the strategies among different clinician specialties to 
understand commonalities or differences in their implementation and use. Specifically, our research 
questions were: (1) How do clinicians in varying outpatient specialties and settings perceive these 
four opioid risk mitigation strategies? (2) What are barriers and facilitators perceived by clinicians in 
the implementation of these strategies? (3) Do these barriers and facilitators vary by clinical setting 
(e.g. primary care vs. outpatient anesthesiology)? 
METHODS 
Study Design 
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To understand how clinicians perceived and used risk mitigation strategies, we conducted in-
depth interviews with clinicians of different specialties affiliated with a medical center from 2016-
2018. Clinicians were offered $250 to participate. During the study period, use of the risk mitigation 
strategies was voluntary. We used constructivist grounded theory (CGT) methodology to guide data 
collection and analysis (20). Participant interviews were focused on obtaining detailed, descriptive 
data. We used a combination of inductive and deductive techniques to analyze the data, which 
involved moving iteratively between collecting, reflecting upon, and analyzing data. Inductive 
techniques involved creating initial codes that defined and labeled participants’ views and actions 
(20). During this stage, we examined study participants’ actions and statements closely, explored tacit 
assumptions, and deconstructed how certain events took place (20). Deductive techniques involved 
identifying initial codes that were more significant or frequently occurring and using these codes to 
sift and sort through the rest of the data (20, 21).  
Study Setting and Participant Selection 
This study took place in various outpatient settings across a large metropolitan area, 
including several primary care clinics, a multidisciplinary pain center, academic medical center 
departments, and private specialty practices. To recruit study participants, we emailed all clinicians 
affiliated with an academic medical center in the ambulatory setting who prescribe opioid 
medications for chronic pain or who treat chronic pain patients, including primary care/urgent care 
physicians and nurse practitioners, outpatient anesthesiologists, dentists who focus on pain 
medicine, physical medicine and rehabilitation physicians, rheumatologists, and neurologists. We 
excluded surgeons and emergency department physicians, as guidelines regarding opioid prescribing 
and use of the risk mitigation strategies for these clinicians are different from other outpatient 
clinicians and thus we felt they fell outside the scope of this study. We interviewed clinicians 
working in private practice, Health Maintenance Organization (HMO) medical groups, and faculty 
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settings. Clinicians interested in participating in the research were told that the interviews were 
focused on clinical decision-making around opioid prescribing. The study was reviewed and 
approved by the academic medical center’s Institutional Review Board. 
Data Collection  
We developed a semi-structured interview guide for the first set of pilot interviews, which 
was refined for subsequent interviews as we analyzed the initial data according to CGT methodology 
(20). The interview guide (see Appendix 1) covered broad topics including the clinician’s approach 
to treating chronic pain and acute pain; discussions about local, state, and health system guidelines; 
and communication with patients about opioid medications. We also specifically asked questions 
about perceptions and use of the opioid risk mitigation strategies. Interviews lasted 45 to 120 
minutes. We audio-recorded the interviews and they were transcribed verbatim by a professional 
transcription service. We wrote fieldnotes to record observations in the field and preliminary memos 
to describe potentially important preliminary codes. We reviewed the transcripts and checked them 
for accuracy based on the audio recordings before analysis.  
Data Analysis 
Following CGT methodology, there was no a priori codebook or theme identification; all 
codes and categories were derived from the data. We gained analytic direction for our study after 
coding the first 10 interviews using line-by-line process coding; thus, each line was coded using a 
gerund to describe the action taking place in each line of the transcript (e.g. believing that the opioid 
agreement does not benefit patient). (22). At this point, we identified the most frequently occurring and 
significant codes. Then, we elevated these initial codes to focused codes, which are more selective 
and conceptual than line-by-line codes. Using these focused codes, we conducted further coding of 
transcripts through an iterative process; if new codes were identified in a subsequent transcript 
during the coding process, we re-read and re-coded the previously coded transcripts as needed (20, 
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23). All subsequent transcripts after the tenth were coded using the focused codes as a guide using 
Dedoose (version 8.0.42, SocioCultural Research Consultants, LLC) (20).  
We analyzed the data identified with focused codes by using the various constant 
comparison techniques described in Corbin and Strauss (2008). For example, we contrasted how 
clinicians of different specialties and in different clinical settings used the risk mitigation strategies. 
We examined how their training, relationships with patients, perceptions of the opioid epidemic, and 
past experiences shaped their views. We also compared clinicians’ own descriptions of why and 
whether they used the strategies with different patients or with patients with whom they had 
different patient-clinician relationships (e.g. new patients vs. established patients).  
RESULTS 
Our sample included 32 clinicians of different specialties who prescribe opioid medications 
in the outpatient setting, including 17 internal medicine physicians, three family medicine physicians, 
one primary care nurse practitioner, four rheumatologists, two neurologists, three anesthesiologists, 
two dentists with additional training in pain medicine, and one physical medicine and rehabilitation 
physician (Table 2). Four primary care clinicians practiced in both the urgent care and primary care 
settings. Most of our clinician sample practiced within an HMO group (53%) or private practice 
(25%); several clinicians practiced in multiple settings (had both a private practice and were part of 
the HMO group, for example). Our sample included clinicians with a wide range of years of practice, 
ranging from clinicians recently out of residency to clinicians who had been practicing 40 years. To 
protect the identities of study participants, we have obscured their gender in this paper. 
Several of our interviews included clinicians working in the same practice group affiliated 
with an HMO with several locations in an urban area. The group is composed of approximately 100 
clinicians, all of whom see primarily privately insured or Medicare patients. During our study period, 
clinicians in this HMO group indicated that their group was beginning a practice-wide 
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implementation process of the opioid agreement, urine toxicology testing, and the PDMP. In 
contrast, anesthesiologists and dentists practicing in the center’s pain clinic reported integrating the 
strategies several years prior. 
Adopters of the risk mitigation strategies were primarily urgent care clinicians and pain 
specialists, including anesthesiologists and dentists with a specialty in pain medicine. Adopters found 
the risk mitigation strategies to be helpful in treating all patients equally, setting limits with patients, 
and providing objective evidence of abuse or misuse. Adopters in the pain medicine setting also 
noted that existing organizational protocols and resources facilitated their use of the strategies (See 
Table 3). 
The majority of Non-adopters of the strategies were primary care clinicians and non-pain 
specialty clinicians, including rheumatologists and neurologists. Non-adopters were concerned that 
three of the strategies – the opioid agreement, urine drug test, and risk screening checklists – would 
disrupt the patient-clinician relationship, were superfluous to actions they were already taking to 
prevent misuse, were unbeneficial to patients, and required difficult conversations about substance 
use and sexual abuse. The PDMP was viewed as less disruptive than the other strategies and more 
widely used among this group. Non-adopters in the primary care setting who viewed the strategies 
positively cited lack of time, resources, and financial incentives to implement the strategies.  
 
1. Reasons why Adopters embraced the risk mitigation strategies 
1.1 Treated patients equally 
Adopters reported that they felt using the strategies on all patients was more fair, as this 
reduced or eliminated the need to trust gut feelings. For these clinicians, the strategies provided 
concrete, objective evidence and reduced the possibility of falsely accusing a patient of drug-seeking 
or overlooking a patient at high risk for overdose or misuse. One family practice clinician noted that 
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they used the strategies because they had been “taught that you can’t tell the book by the cover.” 
They continued: 
So it’s actually if you don’t have that heightened alert for every patient but you have 
to be also non-judgmental and sympathetic… I think that’s where it helps to have 
these uniform rules like I check the [state PDMP] almost every time, pretty much 
every time. I don’t assume. I do that urine tox screen and look to see that it’s in the 
urine what you’re prescribing. 
1.2 Facilitated with setting boundaries 
Adopters often noted the risk mitigation strategies made their jobs “easier” and gave them 
organizational cover to follow their clinical judgment or personal policies. An urgent care clinician 
noted: 
[the opioid agreement] makes it a little easier because we can tell patients they are 
only supposed to have one provider who’s providing their chronic pain medication, 
there’s certain classes of pain medications that we don’t prescribe from the urgent 
care setting, and then now with the [state PDMP] system in place it’s very easy to 
find out kind of the background of a patient’s opiate prescribing or filling 
medications. 
 
Adopters noted they were comforted with the ability to shift the responsibility for using 
these strategies to organizational policy or the government. This allowed then to set limits with 
patients without appearing as non-empathetic clinicians. When patients asked why they used 
strategies such as the PDMP, one clinician said they replied:  
‘Look, as a policy for our center, this is what we do and that's our philosophy and 
this is why we do it, and now it's the government's philosophy.’ And I think [patients 
are] more likely to go along with that and not question as much, especially when you 
say we need to check on your opiate use on [the state PDMP] and, you know, the 
government is watching things more closely because of this crisis, etc. 
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1.3 Provided a way to document misuse, abuse, or diversion 
Adopters also discussed how the PDMP and results from the urine toxicology screenings 
helped them present objective evidence of misuse or abuse to patients. When finding evidence of 
multiple prescribers in the state PDMP, for example, they were able to point directly to the report 
without having to rely on other clues to discuss possible misuse with the patient. One clinician 
stated that having the documentation was important for the discussion:  
First of all, you can show them, ‘Here. Don’t lie to me. This is the list of the doctors, 
the pharmacy [that gave you that prescription].’ So you have a documentation. It’s 
not like arguing with them if they used it. This is what it shows, so don’t argue. [It] is 
a fact. So, yeah, it was very helpful. 
 
Adopters stressed the importance of objectivity and the ability of the risk mitigation 
strategies to produce evidence that allowed them to make decisions about continuing treatment for 
patients on opioids. Clinicians in the pain center setting, who were much more likely to be Adopters, 
discussed experiencing diversion and misuse more frequently. One clinician discussed discharging 
three patients in their practice within one week because of urine toxicology tests that came back 
without the presence of an opioid, giving them objective evidence that the patients may have been 
diverting their opioids. With this evidence, the clinician sent letters to patients informing them that 
they were being discharged from the clinic and that the clinician would no longer be continuing their 
opioid medications.  
1.4 Routine and systematized protocols made use seamless 
Adopters in pain center and urgent care settings described a protocolized system where the 
risk mitigation strategies were standardized and routinely used. In the pain center setting, opioid 
agreements, urine toxicology screens, and state PDMP checks were routine practice. Adopters in this 
setting described the pain agreement as “no big deal” and routine: “We do drug tests, urine tox 
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screen, random urine tox screen. We do [state PDMP] support which shows you if they get the 
medication from other provider,” explained one anesthesiologist. Administrators supported and 
encouraged use of the risk mitigation strategies. Nursing staff at the pain center went over the opioid 
agreements with patients, eliminating the need for clinicians to go over this task. 
Urgent care clinicians also described having a structured routine for checking the PDMP. 
One internist described how they prepared for a patient visit by checking the chief complaint from 
the medical assistant, and if the chief complaint included a diagnosis such as low back pain, they 
would look up and print the PDMP report so they could discuss it with the patient. 
I can show them, ‘Look, I’m mandated to run this report if I’m going to prescribe 
these classes of medications, I can see that you’ve had it filled from this many 
providers, and this was the most recent time, and this was the number of pills you 
were given.’ If I’m upfront from the beginning with patients, they know that we’re 
going to start out with that baseline of transparency and they’re going to be less likely 
to hide the real story… 
The internist preferred being armed with the PDMP report before walking into the room to be able 
to have a frank conversation with the patient from the start, which prevented an uncomfortable 
confrontation later in the visit: 
It’s been times maybe even before we started rigorously checking [the state PDMP], 
where a patient would tell you a story and it just seemed a little off and then you 
would go run the [state PDMP] report and then when you go and you kind of have a 
confrontational relationship with that patient because you’re like, ‘you told me one 
thing, now I see this,’ and they may argue what’s in the [state PDMP] report, so it’s 
not a good place in the patient-physician relationship at that point. Whereas, if we 
just set the stage right off the bat, ‘Look, I have to run this report when you’re 
prescribed these medications,’ and they know that I can see all of that ahead of time, 
it’s a different conversation and often a much easier conversation. 
2. Non-adopters and barriers to use of the opioid risk mitigation strategies 
 
2.1 Disruptive to the patient-clinician relationship 
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Non-adopters of the risk mitigating strategies were uncomfortable using the opioid 
agreement and urine drug testing. They perceived that these strategies would upset established 
relationships with patients. Non-adopters perceived that these two strategies treated all patients with 
distrust or as “drug addicts,” as one clinician noted. Conversations about the opioid agreement, 
particularly with patients who had been receiving opioids for many years, reportedly felt awkward 
and uncomfortable, and were “a pain the butt.” One internist said they were “embarrassed” to give 
the opioid agreement to patients, feeling uneasy about the “obnoxious” bold print used throughout 
the agreement. Another internist described an interaction where a patient got “very upset” and was 
“really offended” when the clinician introduced the pain agreement. The internist described the 
patient’s reaction to the agreement: “you think I’m going to become a drug addict or something, or 
abuse this.” The vivid, unpleasant experience led this internist to refer out patients whom they 
suspected of misusing opioids. 
The nature of urine drug tests, where a clinician is using a tool to check if patients are taking 
their prescribed opioids or using illicit drugs, also bothered several Non-adopters, as it implied a lack 
of trust and knowledge in their established patients. Explained one internist: 
 
I don’t need to do a tox screen on my patient that I’ve known for 15 years who’s got 
a lovely wife and an established business, who’s got terrible arthritis in his knee and 
he can barely walk down the hall, and I see him [in] agony every step he takes.  
For non-adopters, the PDMP felt the least adversarial of the strategies. It was the one strategy 
several Non-adopters reported using regularly. Using the PDMP requires no interaction with the 
patient unless there are troubling findings. One primary care clinician generally used the PDMP 
because they felt it gave the clinician concrete, objective evidence, rather than drawing on 
impressions about a patient:  
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Usually I just draw the line at the [PDMP]. These are folks who have had opioid 
misuse issues… the proof is going to be in their actions, not in their words, not in 
the way that they dress, not in their other concurrent issues. 
2.2 Unnecessary given close relationships 
 
Non-adopters  reported that the risk mitigation strategies felt superfluous for three reasons: 
they knew their patients well, they felt confident in their ability to detect misuse or abuse, and they 
did not perceive that they had abusive patients in their practice. Non-adopters contended that the 
long-term relationships they formed with patients gave them enough information to make decisions 
about their patients’ risk for misuse or abuse. They relied on identifying troubling patient behavior, 
such as repeated calls for early refills or aggressive behavior with medical staff, to detect if the 
patient was at risk for misuse or abuse. In fact, Non-adopters often described that if they felt the 
need to use strategies such as urine drug testing or the pain agreement, it was a signal that the 
patient-clinician relationship was damaged. At this point, they preferred to refer the patient out to 
another clinician. One internist explained: 
I personally do not have them sign a contract and all the stuff that pain specialists 
do. That’s kind of why I want them on my team, because honestly, I just don’t have 
the time to go through all that, and if I feel that there's somebody breaking that 
verbal relationship or trust, I’m sending them to pain medicine anyway. 
 
Similarly, rheumatologists who were non-adopters said they did not use the opioid agreement or 
urine drug testing but referred patients who they deemed at high risk of misuse out to either primary 
care clinicians or pain specialists. One rheumatologist who practiced in an academic medical setting 
explained that they viewed the need to use urine drug testing as a reason to refer the patient out 
because the trusting relationship was broken: 
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I do not do urine drug testing. If I reach a point where I need to do urine testing, I’m 
not believing someone’s story, I’m referring them out to a pain clinic.  
 
Non-adopters described workarounds to detect potential diversion or misuse, including 
examining previous records or questioning dubious requests. They reported feeling confident in 
their ability to detect misuse or abuse. One internist explained: “I’ve got a pretty good sniffer as to 
who’s bullshitting me and who’s not.” Several clinicians described how they listened for suspicious 
requests from patients, including mentions of allergies to non-opioid analgesics. One internist 
described: 
They’ll tell me that, ‘no, I tried that medicine, this medicine had side effects, I was 
allergic to that, but I kind of like this medicine.’ And sometimes they’ll fumble with 
the name a little bit. You know, ‘oxy-crodon’ or something…. I don’t let them know 
up front that I’m suspicious of them. I always give people the benefit of the doubt, 
but these are things that I look for. 
Additionally, we found a consistent perception among Non-adopters in our sample that they felt it 
was not their patient population abusing these medications, and therefore the risk mitigation 
strategies were unnecessary. “I don’t have those types of patients,” explained one internist. One 
rheumatologist used language that was repeated over and over by several clinicians. Referring to 
whether they used the PDMP, they said:  
Honestly, I haven’t needed to. I really have not been in a position certainly in the 
past 4 or 5 years where I’ve felt like somebody’s using a lot of drugs and maybe 
doctor shopping. 
This clinician also felt that they didn’t need to use the opioid agreement because they didn’t have 
“any patients in my current practice who I’ve found to be abusive of the privilege.”  
2.3 Unilateral and unfair to patients 
Non-adopters perceived the strategies to be unilateral and unfair to patients. Instead of a 
written opioid agreement, which felt authoritarian, Non-adopters used workarounds such as verbal 
   18 
discussions with their patients to outline the risks and potential adverse effects of, and expectations 
for, taking opioids. A family practice clinician formerly used opioid agreements, but stopped using 
them because they felt that:  
A lot of folks don’t want to sign the agreement because again, it's kind of like 
admitting, ‘Hey, you're the boss. You have all the power. I'm giving everything up.’ 
All the terms in the agreement are for my benefit. There's nothing in there for their 
benefit, so they really do feel like they're signing everything away. 
Requiring urine tests that did not provide additional benefit to the patient also gave non-adopters 
pause. One clinician felt that they weren’t adequately administered with the patient’s full consent and 
were unethical. Another clinician felt that using sophisticated urine drug tests could be too costly for 
patients. For higher-risk patients, they felt these tests might be appropriate, but they wouldn’t use 
these tests on all of the patients because the financial costs to patients outweighed the benefits.  
Non-adopters expressed concern that patients were already stigmatized for taking opioids 
and didn’t want to introduce risk strategies that further stigmatized these patients. One internist 
expressed a concern about not pre-judging patients when discussing the use of the PDMP:  
Frankly, I mean I’m so old school I try not to look at old records with a new patient. 
I want to go in fresh and form my own opinions and then obviously I don’t 
disregard old stuff. 
1.4 Require broaching taboo topics 
Checklists such as the Opioid Risk Tool often require asking sensitive questions about 
personal and family history of substance use and history of preadolescent sexual abuse, topics which 
Non-adopters found difficult to broach. One internist described that they felt the Opioid Risk Tool 
posed questions about topics that they felt they would be uncomfortable answering:  
But you know if I were going for hip surgery and somebody gave me one of these or 
said you have a personal history of substance and so forth… I’m not sure I would 
really like that… it is tough to ask these questions. 
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Very few Non-adopters reported using strategies such as the Opioid Risk Tool. Others developed 
workarounds, using the tools as rough mental checklists instead of actually filling them out. One 
clinician explained their modified process to identify risk for misuse or abuse: 
So if it’s acute pain, I don’t necessarily do the whole Opioid Risk Tool, but I’ll at 
least be like… alcohol, drug history, and I’ll check the [PDMP]. 
1.5 Difficult to implement given the lack of time, protocols, and incentives 
A few Non-adopters viewed the risk mitigation strategies positively. Among these Non-
adopters, the main barriers to implementation were lack of time, protocols, and resources to 
implement the strategies. In particular, the lack of a structured process that integrated the four risk 
mitigation strategies into the clinical workflow posed a major barrier. Several clinicians contrasted 
this lack of an integrated workflow to the clear protocols that had been developed for treating 
patients with diabetes or hypertension. The current system required individual providers to 
remember all of the individual components, “and painstakingly go and collect all that information 
and synthesize it,” explained one internist. Protocols also appealed to clinicians because they allowed 
them to depersonalize the decision to use it. One internist described that they would prefer “making 
[the pain agreement] standard, so that we don’t feel bad asking a patient to sign an agreement. We 
can say ‘Listen, this is policy and this is what we need to do.’” 
In the primary care setting, limited time was also a significant barrier. Clinicians mentioned 
how integrating a discussion involving the opioid agreement – a multiple-page document – into a 
rushed primary care visit was difficult. Going over the agreement often took as long as 40 minutes, 
far longer than the time allotted for most primary care visits. One internist said they would use the 
opioid agreement more often if there was a clear workflow where clinical staff could begin the 
conversation, reducing the time burden on the physician: 
I think [the opioid agreement is] a very useful tool. For me, personally, it’s somewhat 
time consuming if you don’t have it part of the workflow… So, something that your 
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staff can pull up and then start the conversation and then you can complete it. Those 
tend to be the most successful forms-oriented encounters. 
The lack of incentives to add these additional processes also played an important role for 
some Non-adopters. One internist regularly checked to see how they were doing on things like 
blood pressure checks and diabetes goals, but “at the end of the year when you receive your pay plan 
and someone looks at how well you’re doing, there is no similar quantification of care for pain.” 
They cited the lack of incentives from the federal government or insurers for this lack of a protocol:  
There is no systematic marker for pain management. Which is, in my opinion, the 
real reason why we don’t have a solution. Because if someone said, ‘You’re going to 
get paid based on how well you do this,’ you can be sure the ducks are going to get 
lined up pretty quickly. Because it will be part of your pay-for-performance 
dashboard. 
Finally, inertia played a role for some clinicians. Several primary care clinicians who had been 
in practice for many years reported that they had not integrated checking patients’ prescriptions 
using the PDMP. They initially attempted to use the state database several years ago, but found it 
difficult to use and had not logged back in. They resorted to their own workarounds to detect 
aberrant behavior such as checking the chart or relying on cues about the person’s demeanor.  
DISCUSSION 
In this qualitative study using a sample of clinicians practicing in outpatient settings, we 
found that adopters felt protected by these strategies, as they allowed them to point to objective 
evidence when setting boundaries with or pushing back against patients. These perceptions were 
voiced by clinicians in the urgent care and pain management settings, where care is more episodic 
and there are fewer concerns about damaging existing therapeutic relationships. Adopters also 
pointed to set protocols and resources available to implement the strategies. Non-adopters of the 
strategies described several barriers to use, including concerns about the disruption of the patient-
clinician relationship, lack of usefulness of the strategies, lack of benefits for patients, a desire to 
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avoid taboo topics such as history of substance use and sexual abuse, and lack of protocols, time, 
and incentives. These concerns were primarily voiced by clinicians in primary care and non-pain 
specialty settings, where long-term relationships are prioritized.  
Our findings have important implications for clinicians, health systems administrators, and 
policymakers. In our study, Non-adopters voiced concerns about how the opioid agreements could 
introduce a significant power differential between patients and clinicians. Others have found similar 
perceptions about the strategies’ potential to disrupt patient-clinician relationships (19). Our findings 
lend support to concerns raised by critics of risk assessment strategies, who note that their use may 
impede or harm the important therapeutic relationship between patients and providers and conflict 
with clinicians’ ethical principles (24-27). Buchman and Ho argue that strategies such as the urine 
drug test and the opioid agreement assume the patient is untrustworthy, which can undermine the 
credibility of the patient’s story: “If patients distrust their physician, or feel distrusted by them, this 
may destabilise the therapeutic relationship and compromise care” (24).   
Administrators, policymakers, and researchers focused on improving adoption of these risk 
mitigation strategies should examine ways in which the strategies can be co-designed with clinicians 
and patients to minimize disruption to the patient-clinician relationship. For example, there have 
been several efforts to make some of these risk mitigation strategies more patient-centric and easier 
to implement, which could increase their uptake (28-30). Several have argued that opioid agreements 
and urine drug testing should be eliminated altogether in favor of shared decision-making aids. 
Tobin et al. (2016) describe the development of an opioid agreement that would be used in the 
context of shared decision-making (30). The proposed checklist contains physician and patient 
responsibilities in easy-to-understand language without legal jargon. Health system administrators 
and clinicians may consider switching from opioid agreements that contain terms primarily for the 
provider to shared decision-making tools that build on the patient-clinician therapeutic relationship. 
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Non-adopters in our study revealed their values as they spoke about reasons for not using 
the strategies. They cited concerns about fairness and not wanting to further stigmatize patients. 
Implementation is most effective when there is a good fit between the values underlying an 
innovation and the values of those implementing the innovation are aligned. In 1996, Klein and 
Sorra introduced a model to explain key determinants of implementation effectiveness (31). Within 
this model, one important determinant is whether there is a perceived fit between the innovation 
and the values of the employees (31). When the innovation-values fit is poor, there may be 
resistance or lackluster compliance even where the organization is committed to implementation. In 
our study, when clinicians found that certain opioid risk mitigation strategies conflicted with the 
patient-clinician relationship or were unfair to patients, they found workarounds or complied only 
partially. For example, clinicians opted for verbal agreements instead of written agreements or 
avoided most strategies. Without meaningful buy-in, these risk mitigation strategies could become 
perfunctory checklists instead of thoughtful conversations about the risks of opioid medications, 
concerns that others have raised as well (32). Ensuring that the strategies are designed and aligned 
with clinicians’ values is critical to adoption.  
 Another important determinant of implementation success described by Klein and Sorra is 
the organization’s climate for implementation (31). Klein and Sorra posited that organizations can 
create a climate where employees are encouraged, cultivated, and rewarded for the use of a given 
innovation. We found that clinicians in the urgent care and pain clinic settings who were most 
comfortable with using these strategies cited a strong and effective climate for implementation at the 
clinic level. Clinicians working in the pain clinic setting referred to management that was supportive 
of the use of the strategies, protocolized processes for use of the strategies, and allocated resources 
for the implementation of the opioid agreement and urine drug testing. In contrast, the few primary 
care clinicians who embraced the strategies felt that the lack of protocols and resources allocated to 
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implementing these strategies hindered their adoption, findings that others have identified as well 
(33-35). To reduce barriers to implementation, organizations should consider ways in which non-
physician staff could implement some of these strategies to reduce the administrative burden on 
primary care clinicians. On a policy level, many states currently only allow physicians to access the 
PDMP; policymakers should consider legislation that allows medical staff such as medical assistants 
to check these state databases to increase use without overburdening providers. 
Our study has some limitations. We interviewed clinicians who mostly see insured patients in 
one metropolitan area, which may limit the applicability of our findings to similar practice settings. 
We also examined only perceived use of the risk mitigation strategies and were not able to examine 
documented adoption; future studies using mixed methods could examine both documented use and 
clinicians’ and patients’ perceptions. Our study also has several strengths. The majority of studies 
have focused on studying these strategies in isolation, whereas we examined their use collectively, 
which provided insights into similar barriers to use for different strategies. Additionally, most studies 
focused on the use of these strategies in the primary care or emergency department settings; our 
study is one of the few that examined the use of the strategies among rheumatologists, neurologists, 
and clinicians in pain management settings.   
 In conclusion, we found that in settings where patient-clinician relationships are important, 
risk mitigation strategies perceived by clinicians to harm the patient-clinician relationship or to have 
little benefit to the patient were less likely to be implemented. In settings where care is more 
episodic and the patient-clinician relationship is less important, the strategies felt useful and 
protective. Given the risks of opioid medications and their potential for abuse, clinicians need 
effective tools to communicate the risks and benefits of opioids to patients and assess risk of opioid 
misuse. However, it is critical that these different types of relationships be acknowledged when 
designing and implementing these risk mitigation strategies. 
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Table 1. Description, Implementation, and Evidence of Risk Mitigation Strategies 
Risk Mitigation Strategy Description Evidence Base Use 
Opioid Agreement Agreements or contracts 
that outline expectations 
of how opioids will be 
prescribed and 
monitored. 
Weak, limited evidence that 
opioid agreements reduces 
misuse (10). 
Widely used (36). Included 
in the 2016 CDC guidelines 
(2). 
Prescription Database 
Management Programs 
(PDMPs) 
State monitoring 
programs that track 
controlled medications 
dispensed from 
pharmacies. 
Mixed evidence on their 
effectiveness, likely resulting 
from heterogenous state 
programs and implementation 
(37). Evidence of reduction of 
multiple prescribers per 
patient, decrease in monthly 
quantity of opioids dispensed, 
and total opioids dispensed 
(12, 37). 
49 states have implemented 
PDMPs, at least 34 states 
are now requiring 
prescribers and/or 
dispensers to check the 
databases before 
prescribing (38). Included 
in the 2016 CDC guidelines 
(2). 
Urine Drug Testing Clinicians use urine drug 
testing to look for the 
presence of the 
prescribed controlled 
medication as evidence 
of use. Urine drug testing 
can also be used the 
presence of illicit or non-
prescribed controlled 
medications. 
Weak, limited evidence that 
urine drug testing reduces 
misuse, overdose, or diversion 
(8, 10). 
Widely used, recommended 
by professional medical 
societies and the CDC (6, 
13). 
Risk Screening Tools: 
Screener and Opioid 
Assessment for Patients 
with Pain-Revised 
(SOAPP-R), the Brief Risk 
Interview, Opioid Risk 
Tool, Current Opioid 
Misuse Measure (COMM) 
Clinician-directed or 
patient self-assessments 
to screen for risk factors 
or aberrant behaviors 
associated with opioid 
misuse. 
No evidence that these tools 
reduce addiction, abuse, 
misuse, or overdose (2, 6, 39). 
Limited, inconsistent evidence 
that the tools predict opioid 
abuse and misuse (39). 
Some tools (COMM) 
recommended by 
professional medical 
societies (6). 
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Table 2.  Study Participant Characteristics: Clinicians Who Prescribe Opioids in the Outpatient Setting 
(N = 32) 
Mean Years in Practice, mean (range) 19.1 (2-40) 
Sex, no. (%)  
Male 18 (56%) 
Female 14 (44%) 
Clinician Specialty, no. (%)  
Primary Care  
(e.g. Internal Medicine, Family Medicine) 20 (62%) 
Pain Specialist  
(e.g. Anesthesiology, DDS with Residency in Pain Medicine) 6 (19%) 
Non-Pain Specialist  
(e.g. Neurology, Rheumatology) 6 (19%) 
Practice Type*   
Health Maintenance Organization Group 17 (53%) 
Private Practice 8 (25%) 
Faculty 3 (9%) 
Pain Clinic 5 (16%) 
*Totals may exceed 100% due to individuals in multiple categories 
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Table 3. Reasons for non-use and use of risk assessment strategies from clinicians identified as Adopters 
and Non-adopters 
 
Adopters reasons for using the risk mitigation 
strategies 
Non-adopters reasons for not using the risk mitigation 
strategies 
• Treated patients equally 
• Facilitated with setting boundaries 
• Provided a way to document misuse, abuse, 
or diversion 
• Routine and systematized protocols made 
use seamless 
• Disruptive to the patient-clinician relationship 
• Unnecessary given close relationships 
• Unilateral and unfair to patients 
• Require broaching taboo topics 
• Difficult to implement given the lack of time, 
protocols, and incentives 
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CHAPTER 2: Appendix 1: Sample questions from Semi-Structured Interview Guide 
 
 
1. What does the typical assessment look like for someone’s first time pain-related visit?  
a. PROBE Can you guide me through what happened at a recent office visit for a 
patient who came in for pain? 
2. What are the main factors that influence your decision to prescribe opioid medications?  
3. Upon prescribing an opioid pain medication for the first time to a patient, what kind of 
discussion do you have with them?  
a. PROBE Could you give me an example of a recent conversation that you had with a 
patient?  
4. What do you think about the PDMP? Is it useful? When is it most useful? When is it 
least useful or you find that you don’t need to use it? 
a. PROBE: Can you tell me about your encounters last week? Did you check the 
PDMP? 
5. What are your thoughts on opioid or pain contracts? Do you find them useful or not 
useful?  
a. PROBE: Can you tell me about the last time you used a pain contract? What 
was that conversation like? 
6. What are your thoughts on urine drug testing? When do you use urine drug testing?  
a. PROBE: Can you tell me about the last time you used this test? 
7. Have you used tools to assess patients for risk such as the Opioid Risk Tool? When 
was the last time you used the tool? 
8. Do you discuss substance use with your patients?  
a. How does that information affect your decision-making? 
9. What do you think about the media coverage of opioids? Has this changed your 
practice in any way? 
10. What are your thoughts of how health systems are handling opioid prescribing? 
11. Have there been changes to how you think about prescribing opioid medications over 
the last few years? 
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CHAPTER 3: Study 2 : Understanding Clinicians’ Decisions to Assume Prescriptions for 
New Patients on Long-Term Opioid Therapy 
 
ABSTRACT 
 
Background 
Given the changing political and social climate around opioid medications, we examined how 
clinicians in the outpatient setting made decisions about assuming the management of opioid 
prescribing for patients new to their practice who were already on long-term opioid therapy for 
chronic pain. 
Methods 
The study design, interview guides, and coding were guided by constructivist grounded theory 
methodology. We conducted in-depth interviews with 32 clinicians in the Los Angeles area who 
prescribed opioid medications in the outpatient setting for chronic pain as part of a larger study into 
decision-making about prescribing opioids.  
Results  
Our sample included 21 primary care clinicians, including 17 internal medicine physicians, three 
family medicine physicians, and one primary care nurse practitioner; 6 clinicians with specialized 
training in medicine, including three outpatient anesthesiologists, two dentists with training in pain 
medicine, and one physical medicine and rehabilitation physician; and 6 other specialists, including 
four rheumatologists and two neurologists. We identified three approaches to assuming a new 
patient’s opioid prescriptions. The Staunch Opposers expressed the most anti-opioid views and were 
highly averse to continuing opioid prescriptions for new patients. These clinicians, mostly clinicians 
with specialized training in pain medicine, declined to see patients already on opioid therapy or 
refused to assume the opioid prescriptions in the first visit. Our second group, the Cautious and 
Conflicted Prescribers, were generally uneasy about prescribing opioid medications for chronic pain, but 
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were willing to refill new patients’ existing opioid prescriptions if the patient was perceived as 
trustworthy and if the dose and medication type fell within their pre-set comfort zone. This group 
was composed of clinicians in a variety of specialties. Our third group, the Rapport Builders, mostly 
primary care physicians, were the most willing to assume a new patient’s opioid prescription, even if 
the prescription was for a high dose. These clinicians were often strategic in their approach to 
transitioning patients to safer doses, working to form a strong clinician-patient bond before 
introducing the idea of reducing the dose or tapering down medications. Clinicians in the first two 
groups described feeling resentful about other clinicians “dumping” patients on chronic opioid 
therapy on them, while clinicians in the third group often viewed managing new patients on opioid 
therapy as an opportunity to transition patients to safer doses. 
Discussion 
In this single institution study, we found that clinicians with the most training in pain management 
were the least willing to assume responsibility for patients already on long-term opioid therapy. In 
contrast, a subgroup of primary care clinicians, who traditionally have had the least pain 
management training, were the most willing to assume this responsibility. This creates a challenge 
because primary care clinicians face several existing barriers to providing high-quality care for 
patients with complex pain conditions such as short visit times and less specialized training. If 
clinicians with pain specialty training are unwilling to manage patients on long-term opioid therapy, 
primary care clinicians’ ability to refer complex cases may limited and they may need more training 
to support their roles.  
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INTRODUCTION 
 In the last several decades, perceptions of opioid medications for the treatment of chronic 
pain have changed dramatically, with a corresponding swing in prescribing behavior. The medical 
and cultural zeitgeist has swung from perceiving opioids as highly addictive and prone to misuse, to 
seeing opioids as helpful for chronic pain, and back to perceiving these medications as addictive and 
dangerous. Caught in the middle of these swings have been individuals with chronic pain, many of 
whom were prescribed opioids in an era when opioids were perceived as appropriate for long-term 
use and freely prescribed. While many individuals remain on prescription opioids, clinicians are now 
more reluctant to prescribe these medications. Such individuals, who may be physiologically and 
psychologically dependent on opioid medications and may be seeking prescribers, have been 
referred to in the medical literature as “inherited patients” (1).  
Despite volumes of literature on the opioid epidemic, little has been written about how 
clinicians decide whether to take on the opioid prescriptions of “inherited patients.” This decision-
making process has important societal implications; if individuals cannot find a clinician to continue 
their opioid medications, they may experience severe withdrawal symptoms and turn to illegal drugs 
to avoid withdrawal (1). Understanding this decision-making process can provide insight into 
potentially negative perceptions that clinicians may have about patients taking opioids for chronic 
pain.  
This paper describes how clinicians make decisions about assuming opioid prescriptions for 
patients new to their practice and already on long-term opioid therapy. First, we review the literature 
on the evolution of perceptions of opioid medications and the implications of these shifts in 
perception. Subsequently, we outline our study methods, an analysis of qualitative interviews 
conducted with a sample of clinicians in Los Angeles, California. In our results, we describe a 
continuum of how clinicians approach assuming opioid prescriptions for new patients on existing 
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opioid therapy. We categorized clinicians into three groups depending on their approach to 
managing these patients and discuss the implications of their decision-making approach. 
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BACKGROUND 
 
The changing landscape of opioid prescribing 
The rise of the opioid epidemic has resulted in a marked shift in recommendations about 
prescribing opioids. Prior to the 2000s, opioids were reserved for post-operative pain, palliative care, 
and cancer-related pain (2). A confluence of factors, including changing views about how to treat 
chronic pain (3), the release of strong opioid medications such as OxyContin, and the heavy 
marketing of opioids to clinicians (4) resulted in a marked increase in opioid prescriptions (3). In 
2012, at the peak of opioid prescribing, providers wrote 82.5 opioid prescriptions per 100 persons in 
the United States (5). Clinicians prescribed opioids for more individuals, for longer lengths of time, 
and often at higher doses, resulting in more individuals at risk of addiction, drug overdose, and 
death (6). Individuals in the United States were prescribed twice as many opioids per capita than the 
second-ranked nation (7). The last decade has seen a spike in opioid-related deaths, emergency 
department visits, and hospitalizations, many tied to prescription opioids (6, 8, 9). This rise in 
overdoses and deaths led the Centers for Disease Control and Prevention (CDC) to release 
guidelines regarding opioid prescribing in 2016 (10). These guidelines, along with guidelines from 
other medical societies (11-13), now recommend that clinicians optimize non-opioid therapies and 
use the lowest dosages possible to achieve realistic functional goals. In addition to new guidelines, 
dozens of state laws now focus on regulating opioid prescribing, limiting initial doses and the 
number of days prescribed (14).  
The challenges of managing “inherited patients”  
This regulatory climate, coupled with increased media coverage of the opioid epidemic (15), 
has placed great scrutiny on prescribing behaviors, increasing clinicians’ discomfort with prescribing 
opioid medications (15). Providers report feeling fears of prosecution or regulatory scrutiny for 
inappropriate prescribing of opioids (1, 16, 17). There have been several reports that clinicians have 
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abruptly stopped prescribing opioids for many patients, resulting in patients with chronic pain 
feeling abandoned and without treatment (18-20). Clinicians may fear taking on patients on long-
term opioid therapy and feeling trapped in a situation for which they do not agree with the regimen. 
In an article about recommendations on how to manage “inherited patients” on long-term opioid 
therapy, Gourlay and Heit note:  
 
…a very real barrier to undertaking the care of a new patient who is on a complex 
regimen of medications, especially opioids, is the fear that once they accept the 
patient into their practice, [clinicians] will have no choice but to continue on with 
this course of therapy, even if all reasonable assessments would suggest that it is not 
optimal (1). 
 
Gourlay and Heit recommend that clinicians start with an initial visit of “mutual fact 
finding,” in which the patient and clinician assess whether the relationship will be a good fit. 
Although the authors suggest a “mutual” process, most of their article concerns actions that the 
clinician should take, including assessing whether the opioid therapy is appropriate, whether the 
patient has psychiatric comorbidities, or whether the patient has a personal or family history of 
substance-use disorder or an active substance-use disorder (1).  
Despite these recommendations, it is not well understood how clinicians approach managing 
“inherited patients” in practice. The literature on managing “inherited patients” is scant. Owston 
also recommends an initial assessment with a thorough history, review of previous records, and 
assessment of risks for overdose, diversion, or abuse (21). Understanding this process can provide 
insight into what Gourlay and Heit refer to as not only a problem for patients, but also: 
 
a societal problem…When legitimate pain patients are deprived of the opioid 
medication they have been taking, this can lead to an immediate crisis situation… 
Patients traveling long distances to obtain medication, frequenting multiple 
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emergency departments or walk-in clinics, or engaging in frank criminal behavior 
may be a direct result of these patients trying to solve this problem (1). 
 
Others have also written about how clinicians’ aversion to prescribing opioids has led to 
patients on chronic opioid therapy feeling highly stigmatized and having to travel long distances to 
obtain their prescriptions (22).  
Although these studies highlight the potential consequences of clinicians’ reluctance to 
prescribe opioids, we wanted to identify the reasoning behind this reluctance and how clinicians 
acted on this reasoning. Thus, in this study, we sought to understand how clinicians in outpatient 
settings made decisions about assuming opioid prescriptions for new patients on long-term opioid 
therapy by using our sample of clinicians practicing in the Los Angeles area. We examined how 
clinicians in different settings interacted with individuals in chronic pain who are on long-term 
opioid therapy, and so included clinicians in primary and specialty care (neurology, pain 
management, rheumatology) settings to observe the interactions with “inherited patients” between 
these groups of clinicians. We examined the types of strategies they used in assessing whether to 
assume new patients’ opioid prescriptions.   
METHODS 
This study is part of a larger study aimed at understanding how clinicians prescribe opioid 
medications in the outpatient setting. In other papers, we examine how clinicians perceive and treat 
the side effects of opioid medications, and how they use various risk assessment strategies aimed at 
reducing opioid misuse, abuse, or diversion.  
Sample 
For the larger study, we interviewed 33 clinicians who prescribed opioid medications and 
were affiliated with an academic medical system in the Los Angeles area; of them, 32 clinicians 
reported they worked in an outpatient setting. We used purposive sampling techniques to identify 
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potential study participants in any one of the following specialties: internal medicine, family 
medicine, neurology, rheumatology, physical medicine and rehabilitation, and pain medicine 
(outpatient anesthesiology and dentistry with a specialization in pain medicine). We excluded 
clinicians in the emergency department and surgical specialties given that opioid prescribing in these 
settings is very different and subject to other guidelines. We emailed potentially eligible clinicians 
within the medical system. Clinicians were offered $250 to participate. The study was reviewed and 
approved by the Institutional Review Board at the study site.  
Setting 
Clinicians in our sample had inpatient privileges at one tertiary care academic medical center 
and worked in various outpatient settings in the Los Angeles area including private concierge-style 
practices or those that accepted only limited insurance plans, such as Medicare and preferred 
provider organization (PPO) plans; Health Maintenance Organization (HMO) groups; urgent care 
clinics; a specialized pain center; and an academic medical center. Some clinicians worked in more 
than one of these practice settings. We sought to interview clinicians with different levels of 
experience, practice settings, payment models, and specialties to capture a wide range of experiences.  
Interviews  
We conducted the interviews from July 2016 to February 2018. We conducted the interviews 
at clinicians’ offices or in a private room at the researchers’ offices. The interviews were 60–120 
minutes in length. One clinician was interviewed twice in order to gather more detailed data. A 
professional transcription service transcribed all interviews, and the transcriptions were checked for 
accuracy. All identifying information was changed to protect confidentiality.  
Coding and Analysis 
We used constructivist grounded theory to guide the coding and analysis for this study (23-
25). We coded the first 10 interviews using line-by-line coding (i.e., “initial coding”) to identify 
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preliminary reoccurring and significant codes (i.e., “focused codes”). Coding is viewed as a way to 
sort, summarize, and analyze each piece of data (23). From this preliminary coding, we wrote memos 
that identified potential focused codes, which are more conceptual codes that identified significant 
ideas within the data. For example, a focused code captured how various clinicians used screening 
strategies to avoid seeing new patients who were looking for a clinician to take over their 
prescriptions. We coded the rest of the transcripts using focused codes, adding to the codebook as 
we developed new focused codes. Throughout the process, we wrote memos using the constant 
comparison method that is core to constructivist grounded theory, identifying areas where there 
were similarities, variations, or differences in the data (23, 26, 27). For example, for this study, we 
wrote a memo to identify, describe, and compare variation in how clinicians assessed whether a 
patient was trustworthy.  
RESULTS 
Study Participants 
For this study, we included data from 32 clinicians, which included 17 internal medicine 
physicians, three family medicine physicians, one primary care nurse practitioner, four 
rheumatologists, two neurologists, three anesthesiologists, two dentists with additional training in 
pain medicine, and one physical medicine and rehabilitation physician (see Table 1). Four primary 
care clinicians practiced in both the urgent and primary care settings. Participants worked in 
different roles: some worked in urgent care practices, the majority worked in outpatient settings, and 
some worked in both urgent and primary care. We interviewed clinicians across Los Angeles 
County; their catchment areas were predominantly middle- and upper-class neighborhoods. 
Clinicians ranged in level of experience, from only 2–3 years out of residency to having more than 
40 years of practice experience. We have obscured the gender of the study participants to protect 
confidentiality.  
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Willingness to manage patients on chronic opioid therapy: A continuum 
We identified a continuum of willingness to take on patients on chronic opioid therapy, 
from clinicians who were strongly opposed to it to those who were more accepting. From this 
continuum, we constructed three categories of clinicians that described this willingness to assume 
prescriptions for new patients already on opioid therapy. One group, the Staunch Opposers, was highly 
averse to taking on new patients already on chronic opioid therapy. These clinicians, mostly pain 
medicine specialists, used a variety of strategies to screen out patients who they suspected were 
looking for a new prescriber. The Cautious and Conflicted Prescribers were generally uneasy about 
prescribing opioid medications for chronic pain but willing to manage new patients if they were 
trustworthy or if the dose and medication type fell within their pre-set “comfort zone.” The Rapport 
Builders, mostly primary care physicians, were the most willing to assume a new patient’s opioid 
prescription, even if the prescription was for a high dose. These clinicians were strategic in their 
approach to transitioning patients to safer doses, working to form a strong clinician-patient bond 
before introducing the idea of reducing the dose or tapering down medications. We describe these 
three groups in detail below. 
Staunch Opposers 
Clinicians identified as Staunch Opposers expressed a high aversion to managing new 
patients already on chronic opioid therapy. These clinicians sought to distance themselves from 
patients on chronic opioid therapy by prescreening patients or making their opposition to opioids 
apparent in the first visit. For example, one rheumatologist who noted they didn’t “like to provide 
narcotics” explained how they approached new patients: “I give [patients] a disclaimer right up front 
that I’m not the right doctor to come to if you just want a prescription for your pain pill.” Several 
clinicians working in a pain center setting, including anesthesiologists and dentists with specialized 
training in pain medicine, described using a structured screening process involving medical assistants 
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or front desk staff to assess whether patients were looking for a new provider who would refill their 
opioid prescriptions. Most of these clinicians had implemented strict no-opioid or low-opioid 
policies and instructed their staff to ask questions about a patient’s reasons for the visit. Clinicians 
described how their medical staff would communicate their no-opioid policies to patients, either 
specifically noting the policies or noting that the first visit was a consultation and that patients 
should not expect a refill for their medication. One clinician summarized their approach: 
 
I mean, if the patient calls [for] an initial consult, at least I know my assistant then 
will tell the patient that this is not how I practice, and I don’t prescribe narcotics, so 
if they’re coming for that purpose, then they’ll just be let down from the get-go. 
 
The prescreening strategy allowed clinicians to assert their autonomy not to prescribe before 
the patient ever walked in the door, which they noted was preferable to having to say “no” in 
person. Clinicians described pushing back against a patient’s demand for a refill, particularly when 
the request was for a regimen with which they would not agree. One anesthesiologist explained: 
 
[Patients will] come with high-dose narcotics, and they expect, ‘Oh, you’re just gonna 
refill my narcotic.’ No, I’m not. Whatever they’ve been doing maybe wasn’t right, 
and I’m not agreeing with that plan. So, yeah. I don’t have to. 
 
Anesthesiologists and other pain specialists in the Staunch Opposer group also described 
perceiving having patients “dumped” on them by other clinicians, including surgeons and primary 
care clinicians who no longer wanted to prescribe opioids, an action they resented. One pain 
specialist explained: “Some internists, they just wanna dump the patient. They don’t wanna deal with 
them… If it’s a dump, they just want us to take over, and [if] we don’t, they get upset.” This 
clinician and others said that they often did not agree with the current dose and frequency and that it 
was very challenging to taper patients down if the patients did not want to do so. By setting no-
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opioid policies, they were able to assert their clinical autonomy not only with patients, but also with 
other clinicians.  
Several study participants said they perceived managing patients on chronic opioid therapy as 
time-consuming, difficult, and not within their clinical interests. They therefore preferred to refer 
those patients to other physicians. One primary care doctor explained they found patients on 
chronic opioid therapy “a pain — excuse the pun — to manage.” The clinician described inheriting 
several patients already on chronic opioid therapy who typically had severe pain conditions and the 
various reasons they preferred not to manage their prescriptions and conditions: 
 
Those are very difficult, and those are the ones [that] generally I’ll refer to pain 
management. But because I think to properly manage these patients, it takes more 
than the usual 15-minute office visit…. [It takes] a dedicated approach that focuses 
on pain management, and it’s a very difficult group of patients, and, frankly, it’s not 
one of my interests.   
 
A neurologist echoed this sentiment, saying that while they previously had managed a few 
patients on chronic opioid therapy, they had switched their practice to doing more specialized 
consultative care. The clinician said they didn’t decline new patients on chronic opioid therapy 
“because of all the craziness that’s going on about the opioid epidemic” but rather because “it’s not 
what I want my role to be.” 
This clinician’s views on the opioid epidemic and of patients on long-term opioid therapy 
were the exception among physicians in this group. Most clinicians in the Staunch Opposers group 
generally viewed opioids and patients on long-term opioid therapy in a negative light. The majority 
of this group perceived opioid medications as largely ineffective for chronic pain, noting that the 
medications not only failed to address the pain but also often caused other problems, such as side 
effects or increased pain. One clinician emphasized that they would “never give narcotics to 
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somebody with chronic migraines… if you look at chronic migraines, it’s the biggest no-no, since 
that’s going to cause more relapse.” Other clinicians pointed to the adverse effects of opioid 
medications as reasons for their aversion to prescribing. One primary care clinician explained: “I’m 
concerned about the adverse effects and also in the older people, all you’ve got to do is give them 
severe constipation, and you can have a problem that’s as bad as what you used the narcotic for in 
the first place.” 
Clinicians in this group also questioned the legitimacy of patients’ needs for the medications 
or viewed their use as problematic. One primary care clinician noted that “the majority of people 
who are not drug addicts don’t like to take [opioids]. [The people who] every day, they’re popping 
six tablets a day, they’re hooked!” The clinician perceived that patients on chronic opioid therapy 
were often on multiple opioid or benzodiazepine medications, some of which the clinician viewed as 
inappropriate. They recalled covering for another clinician who had patients whom the clinician 
described as “Triple V,” calling on a Friday at 5 p.m. for their Vicodin (an opioid), Viagra (an erectile 
dysfunction medication), and Valium (an antianxiety medication). The clinician found the request for 
the combination of all three medications concerning and questioned whether the patient really 
needed these medications. Cautious and Conflicted Prescribers 
 We characterized a second group of clinicians as Cautious and Conflicted Prescribers. These 
doctors approached long-term opioid prescribing cautiously, both in terms of the types of patients 
they were willing to prescribe to and the approach they took when continuing existing opioid 
prescriptions. Cautious and Conflicted clinicians were willing to manage new patients on chronic 
opioid therapy if the dose or medication fell within their “comfort zone,” and if they deemed the 
patient to be trustworthy of managing an opioid prescription safely. Their approach stemmed from a 
perception that opioids were ineffective for long-term use and harmful, and many explicitly 
expressed that they would not start a patient on long-term opioid therapy. As a family practice 
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doctor said: “As far as a chronic pain patient who comes to me not on opiates, I’m never going to 
be the one to start that.”  
To appraise the trustworthiness of prospective new patients on chronic opioid therapy, 
clinicians used information such as whether or not the patient had come from a trusted referral 
source, their perception of the legitimacy of the patient’s pain, and their assessment of existing 
evidence of potential misuse behavior. Whether the patient came from a trusted referral or was self-
referred played an important role in whether clinicians would continue a prescription. Clinicians 
described agreeing to take on patients on chronic opioid therapy from “reliable,” “legitimate,” and 
“trusted” peers. One rheumatologist described their decision-making process:   
There was a patient who was 90 years old-ish and was on Norco, four a day, came to 
me from another physician who retired and had been on that medication for 15–20 
years without changing the dose. [The patient was] compliant in terms of getting the 
prescription, not requesting more than was asked for, and needs it because [she] has 
spinal stenosis and didn’t seem altered in my meeting her... So, although I’m not 
entirely comfortable giving a 90-year-old pain medication, it was the natural thing to 
do rather than stop it. 
 
Self-referrals raised concerns, as clinicians were wary about why the patients were seeking a new 
provider. Participants expressed trepidation that these patients had misused or abused opioids and 
had been discharged by their previous physician. They were also concerned that perhaps the 
relationship had soured with the previous clinician. One internist noted:  
 
So when we see that new opioid patient, obviously we’re not happy about that 
because we know that they failed with another primary care doctor already. 
 
To understand what had happened with previous doctors, several participants asked for previous 
records, and if the patient reacted badly to the request, they refused to refill the prescription. 
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Participants also assessed the legitimacy of the patient’s pain or condition when deciding 
whether to refill a new patient’s opioid regimen, looking for whether patients had diagnoses that 
appeared severe or whether they seemed to demonstrate high levels of pain. One rheumatologist 
described how patients’ severe deformities guided their decision to continue opioid prescription. 
The clinician said they typically got to know the patient over several months, and when they felt 
comfortable, they would take over the opioid prescriptions from the former prescriber: 
 
I have a small cadre of patients who are on opiates because their [rheumatoid 
arthritis] or even their degenerative disease is just so bad and so deforming and there 
are just no other options. And those are the patients [for whom] I will continue [the 
opioid medications].   
 
Clinicians in this group expressed concern for the welfare of their patients on chronic opioid 
therapy, even when they were conflicted about whether or not the prescription was the ideal 
regimen for the patient. One internist explained why they continued to refill the medication for a 
new patient: “I’m his doctor now… you can’t leave ’em hanging out to dry.” Primary care clinicians 
in particular expressed how important it was to develop a relationship with new patients to establish 
continuity of care for all of their concerns. One family practice clinician stated: 
 
I mean, it’s tricky because there are times when even though I feel like it may not be 
the optimal thing, I’ll keep prescribing the medication because I do have this rapport 
with the patient, particularly if I’m seeing them about other issues. Because I don’t 
want ’em to then [go] off the map for their other issues that I’m treating. You feel 
like you have a relationship with the patient, so there is sort of just this kinda 
sympathy thing. 
 
However, the same clinician described conflicted feelings about prescribing long-term 
opioids:  
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I’m trying to really limit it to that… a lot of the patients who I deal with [on] chronic 
opioid therapy — it’s patients whom I’ve inherited, from when I first started out in 
practice… as a primary care doctor, I just don’t want chronic opioid therapy to be 
part of my practice, to be honest. 
 
 Clinicians in this group also described feeling as though patients were “dumped” on them by 
other doctors. Numerous clinicians noted that they had inherited patients from surgeons who had 
started the opioid prescription but no longer wanted to continue prescribing — or, as one 
rheumatologist described it: “hit-and-run prescribing.” Moreover, primary care clinicians described 
being asked by pain specialists to continue prescribing the patient’s opioid medications once the 
patient was stabilized on a regular dose. Study participants expressed their belief that many pain 
specialists were unwilling to continue opioid prescriptions for new patients because they had no 
incentive to do so. There was a perception among participants in this group that anesthesiologists 
preferred to perform procedures such as injections and nerve blocks, which are more highly 
reimbursed than doing office visits for opioid refills. Similarly, many participants, including 
anesthesiologists, felt that surgeons were not incentivized to provide follow-up pain management 
care for their patients given the low reimbursement rate for office visits. As a result, participants in 
this group spoke of the lack of trained and willing clinicians to manage patients on chronic opioid 
therapy as a “big hole in the system.” One primary care doctor described how patients on chronic 
opioid medications bounced around the health care system: 
 
It’s very rare that you find a surgeon that will continue to follow up and manage your pain. 
They’ll end up referring them to a pain specialist if that’s the case… But a lot of pain 
specialists don’t do prescriptions, and then that’s a frustrating area also… Yeah, so then it’s 
on us to handle the pain meds. 
  
Rapport Builders 
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Our third group, characterized as the Rapport Builders, prided themselves on developing 
close relationships and often working collaboratively with patients to decrease doses of opioids that 
they found unsafe. Like the Cautious and Conflicted Prescribers, these clinicians expressed concern 
that their patients would be worse off if they didn’t continue the prescription. However, in contrast 
to the other groups, Rapport Builders were more willing to take on patients already on high doses of 
opioids, often seeing the new relationship as an opportunity to transition patients to a safer dose. 
They worried that if they didn’t become the new prescriber, the patient would end up with a 
clinician who just refilled the prescription without considering the patient’s safety.  
Concern about where patients would end up played an important role in how clinicians in 
this group made decisions about managing new patients on chronic opioid therapy. One family 
practice clinician explained that they were willing to manage a new patient on opioids even if it 
wasn’t a dose that made them “comfortable in any way, shape, or form.” While the dose wasn’t 
within their comfort zone, the clinician worried the patient would end up in a worse situation: 
 
…if you’re not willing to refill that medication and then you’re going turn that 
person on the street and say, ‘I’m not going to be your primary care doctor,’ well, 
then that’s an opportunity you lost like to transition someone to an appropriate pain 
control regimen. And if that person’s motivated, they will find a doctor who’s just 
gonna write the opioids for them and not care and just say, ‘Come back every 30 
days. I’ll give your script. We won’t talk, but I’ll just continue refilling this for you.’ 
There are folks out there that do that. 
 
We heard similar concerns from other Rapport Builders who perceived that other clinicians 
either just refilled the opioids without ensuring the patient’s safety or refused to fill the prescription, 
effectively abandoning the patient. They used these anecdotes as a contrast to their own approach, 
which they described as collaborative and patient-centered. Unlike the Staunch Opposers, the 
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Rapport Builders did not see chronic opioid use as a personal failure of the patient. Rather, Rapport 
Builders attributed the inappropriate opioid prescribing to their predecessors. One family practice 
clinician described how they believed patients often ended up on chronic opioid therapy: 
I think what happens is if you fail a back surgery, the back surgeon either prescribes 
you a fentanyl patch or he sends you to his buddy down the street who’s a rehab 
doctor, maybe a pain medicine doc, and you get on some of these things. 
 
Participants in this group described how others might see the patients as “drug seeking” or a 
“pain in the ass” but noted how some patients were incorrectly diagnosed and therefore incorrectly 
treated with high doses of opioids. Participants described how finding the right diagnosis and 
helping the patient transition to more effective, non-opioid medications was highly rewarding. For 
example, one internist began seeing a new patient who was taking several strong opioids. The 
clinician eventually identified a new diagnosis for the patient, who subsequently stopped taking 
opioid medications: 
 
I found her rheumatoid arthritis, you know, got her the rheumatologist, got her 
treated, and, you know, so she’s now back in the world off of all narcotics. 
 
What also distinguished the Rapport Builders, aside from their willingness to take on 
patients’ opioid prescriptions, was their overall approach to patient care. Several clinicians used 
language such as “I’m not the boss,” as a descriptor of emphasizing patient autonomy and a shared 
decision-making process when discussing chronic pain treatment. These clinicians also described the 
importance of building mutually trusting relationships with patients. One family practice physician 
described how it was important to show patients that they were open to building a relationship and 
demonstrated this by refilling a patient’s opioid prescription: 
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I won't refuse a refill on someone who’s been taking them for years and years and 
years. It's kind of like a bad way of starting a trusting relationship with someone that 
you just met by saying, ‘Oh hey, I’m the boss here, and I think things should go this 
way, and you’re going to listen to everything that I say.’ 
 
As part of this approach, Rapport Builders described not reducing high-dose opioid regimens until 
the relationship was established or, in some cases, until the patient was ready for a change. One 
family practice clinician described getting to know one patient over a year before the patient was 
ready to change to a less potent pain medication. The clinician explained their approach as working 
with patients with the goal of eventually reducing their medications: 
 
It’s like, there’s psychological research on readiness for change, right? A year ago, 
they were not ready, or open or willing to look at something in a different way or to 
change, and then, at some future time, they were. 
 
In sum, we found that study participants in the Rapport Builder group weren’t necessarily in 
favor of keeping patients on high doses of opioids, but they were the most willing of the groups to 
refill prescriptions for new patients on chronic opioid therapy. Rapport Builders also ascribed 
responsibility for the high-dose regimens to other physicians instead of the patients. The Rapport 
Builders, who were mostly primary care clinicians, worked to establish relationships with patients 
before trying to reduce the doses, often using an approach aimed at empowering patients to manage 
their care. 
DISCUSSION 
In this qualitative study of 32 clinicians working in outpatient settings, we found a 
continuum of how participants made decisions about assuming opioid prescriptions for new patients 
already on chronic opioid therapy. On the continuum were three groups, including the Staunch 
Opposers, who were highly averse to managing new patients on opioids, the Cautious and 
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Conflicted Prescribers, who were willing to continue prescriptions if they perceived the patient was 
trustworthy and on low and stable opioid therapy, and the Rapport Builders, who were open to 
assuming prescriptions for new patients already on opioid therapy even if patients were on high 
doses. The last group emphasized building relationships and working collaboratively with patients to 
reduce doses.  
Our findings demonstrate that there may be an important gap in the health system with 
regard to managing opioid prescriptions, especially for patients who require more complex tapering 
regimens and intensive chronic pain management. We found that primary care and non-pain 
specialty clinicians in the Staunched Opposers and Cautious and Conflicted groups described feeling 
frustrated that specialists with training in pain medicine did not want to take over opioid prescribing 
for complex patients or patients on high doses. On the other hand, pain specialists felt that certain 
clinicians, including primary care clinicians and surgeons, prescribed too many opioid medications 
and then “dumped” the patients onto pain specialists. With the large number of patients now on 
chronic opioid therapy, filling this gap will be important to reduce the number of patients at high 
risk for adverse events. Patients who do not have a referring provider because of conflicts with a 
previous doctor or a move may have a difficult time finding a clinician willing to take on their opioid 
prescriptions (20, 22). If clinicians are unwilling to prescribe to these patients, they may go into 
withdrawal or turn to street drugs. For those developing an addiction — a chronic progressive 
disease — lack of high-quality treatment may lead to overdose or death (28). Low reimbursement 
rates for managing chronic opioid therapy may impede proper care (29). Thus, insurance providers 
and health systems should consider developing incentives that allow specialized clinicians to manage 
complex pain regimens in an office visit setting.  
Additionally, our study touches on the marginalization of patients with chronic pain and 
especially of those taking opioids or developing substance use disorders. Many participants in our 
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sample were inclined to refer opioid-using patients out to other providers; this is in line with a 
prolific literature on clinicians’ ambivalence related to treating chronic pain (30-33). As Trait and 
colleagues (2009) noted in a review about provider judgments of patients in pain, clinicians tend to 
have more negative attitudes about patients with chronic pain (32). Patients with chronic pain report 
feeling that clinicians see them as drug-seeking or malingering (34). Other studies have also found 
that clinicians attribute problems with pain care and opioid prescribing to patients, even as they 
recognize that there are existing systemic issues in how chronic pain is managed (34). Additionally, 
in many chronic pain situations, no clear diagnosis exists for the patients’ pain, leading to higher 
levels of suspicion about the legitimacy of the pain and the appropriateness of the pain medications  
(30, 35-37). Our findings suggest that clinicians may have internalized stigma about treating patients 
on chronic opioid therapy. To avoid the many issues associated with managing patients on long-
term opioid therapy, several clinicians in our study developed strategies to eschew prescribing 
opioids altogether. However, these strategies may leave many patients already on opioid therapy 
without access to care. 
Our findings are also in line with studies that demonstrate that many clinicians feel low self-
efficacy and little professional satisfaction in treating chronic pain (30, 33-35). Better training about 
pain management, opioid prescribing, and substance use disorders may help clinicians feel greater 
confidence in treating patients already on chronic opioid therapy. This might increase the number of 
clinicians who could be characterized as Rapport Builders. Future research might examine the use of 
methods such as Conversation Analysis (CA), the systematic analysis of talk (38), to examine how 
Rapport Builders negotiate difficult conversations around dose and tapering with patients. CA has 
been used effectively to examine interactions between patients and healthcare providers (38, 39) and 
can provide a deeper understanding of how Rapport Builders work to develop effective and bilateral 
treatment relationships with patients.  
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Our findings also touch on the issue of clinical autonomy, or the right of medical 
professionals to control their clinical performance (40). Prescribing is an activity that differentiates 
physicians from many other clinical professionals and thus a core component of clinical freedom 
(40). As some have noted, the act of prescribing (or not prescribing) can thrust clinicians into 
conflict with those who threaten their autonomy. The act of refusing to prescribe opioids may be a 
strong assertion of clinical autonomy on the part of certain clinicians within our study. Perceptions 
of patient expectations about prescriptions are also thought to play an important role in clinician 
behavior. Bitten and Okomunne (1997) found that physicians’ perceptions of their patients’ 
expectations to prescribe were the strongest predictor of their final decision to do so (41). Several 
clinicians in our sample spoke of having new patients who expected their opioid prescription to be 
refilled, and clinicians’ screening practices may be an attempt to push back against this perceived or 
actual patient demand.  
Our study has some limitations. Our sample of clinicians serve patients of middle-to-high 
socioeconomic status in an urban area, so the results may be more applicable to clinicians in similar 
settings. We focused on interviewing clinicians in non-emergency, non-surgical settings because 
surgeons and emergency clinicians have different guidelines for prescribing, and we thus felt that 
their prescribing behavior was outside the scope of our study. Still, as a result, our study does not 
include surgeons’ and emergency physicians’ perspectives on seeing patients on chronic opioid 
therapy.  
In conclusion, provider concerns and judgments may be contributing to significant systemic 
issues that affect access for patients on chronic opioid therapy. Our findings provide a basis for 
designing future research with a much larger sample to corroborate and extend our results. If 
confirmed, our results foreground a specific need for addressing providers’ fears and concerns 
related to the care of patients on opioids. Attention is needed to address clinicians who have the 
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most training in pain management since our results indicated they were the least willing to prescribe 
opioid medications for the long-term. Participants in our sample viewed individuals on long-term 
opioid therapy in a negative light. Improving pain management training for clinicians in different 
specialties that focuses on identifying and reducing the stigma surrounding this patient population is 
needed to address the increasingly complex situation of caring for patients with chronic pain.  
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Table 1. Study Participant Characteristics: Clinicians Who Prescribe Opioids in the Outpatient Setting 
 (N = 32) 
Mean Years in Practice, mean (range) 19.1 (2-40) 
Sex, no. (%)  
Male 18 (56%) 
Female 14 (44%) 
Clinician Specialty, no. (%)  
Primary Care  
(e.g. Internal Medicine, Family Medicine) 20 (62%) 
Pain Specialist  
(e.g. Anesthesiology, DDS with Residency in Pain Medicine) 6 (19%) 
Non-Pain Specialist  
(e.g. Neurology, Rheumatology) 6 (19%) 
Practice Type*   
Health Maintenance Organization Group 17 (53%) 
Private Practice 8 (25%) 
Faculty 3 (9%) 
Pain Clinic 5 (16%) 
*Totals may exceed 100% due to individuals in multiple 
categories  
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CHAPTER 4: Study 3: How does opioid prescribing for low back pain differ between 
patients with or without contraindications to NSAIDs or relative contraindications to 
opioids? A retrospective cohort study 
 
ABSTRACT 
 
Background  
Given that the risks of opioid therapy are becoming increasingly apparent, primary care physicians 
are under growing pressure to treat pain with non-opioid medications. Certain individuals may be at 
higher risk for opioid-related overdose or opioid use disorder based on comorbidities and 
concurrent prescriptions. Yet non-opioid medications have their own risks. Patients with certain 
comorbidities and older adults have contraindications to non-steroid anti-inflammatory drugs 
(NSAIDs). Our aim was to examine whether opioid prescribing at primary care visits differed 
among patients with and without contraindications to NSAIDs or relative contraindications to 
opioids.  
Methods  
We used administrative data from a large tertiary care academic health care system. We identified all 
outpatient office visits for low back pain from 2013-2017 and sampled the first visit per patient per 
year (N=21,020 visits). We created separate indicators reflecting contraindications for NSAIDs 
(kidney, liver, cardiovascular, cerebrovascular, and gastrointestinal diseases, and concurrent use of 
anticoagulants, antiplatelets, or systemic corticosteroids) and relative contraindications for opioids 
(depression, anxiety, history of substance use disorder, and concurrent benzodiazepine use). 
Informed by Raisch’s conceptual model of physician prescribing behavior, we also included other 
patient clinical and sociodemographic factors hypothesized to affect patient receipt of an opioid 
prescription, including prior use of opioids. In one model, we controlled for previous opioid use. In 
other models, we stratified by previous opioid use. We used data from the office visit and from 
encounters one year prior to the visit. We used a generalized estimating equations approach to 
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account for multiple visits for each patient over the years and included robust standard errors to 
control for clustering of patients within physicians 
Results 
Patients received an opioid prescription at four percent of office visits for low back pain (865 of 
21,020 visits). After controlling for previous opioid use, patients with kidney disease had 76% higher 
odds of receiving an opioid during the office visit compared to patients without kidney disease 
(aOR: 1.76, 95% CI: 1.31-2.36). Patients with long-term or concurrent antiplatelet or anticoagulant 
medications had 40% higher odds of receiving an opioid during the visit compared to patients not 
taking these medications (aOR: 1.41, 95% CI: 1.16-1.70). We also found that patients with a history 
of substance use disorder, a relative contraindication for opioids, had 45% higher odds of receiving 
an opioid prescription compared to those with no history of substance use disorder (aOR: 1.45, 
95%CI: 1.08-1.19), and that patients prescribed a benzodiazepine, also a contraindication for 
opioids, had 222% higher odds of receiving an opioid prescription compared to patients not 
prescribed these medications (aOR: 3.22, 95%CI: 2.37-4.37).  
Conclusion  
We found that visits for low back pain in which patients had selected NSAID contraindications, 
including kidney disease and concurrent or long-term use of anticoagulants or antiplatelet 
medications, had higher odds of the receipt of an opioid prescription, reflecting potentially 
appropriate prescribing. However, visits where patients had relative contraindications for opioids, 
such as a concurrent benzodiazepine prescription or a history of substance use disorder, had 
significantly elevated odds of opioid receipt, which indicates that some opioid prescriptions may be 
inappropriate. Quality improvement methods such as tailored educational outreach should include 
patient comorbidities to help clinicians and clinical pharmacists identify potentially appropriate and 
inappropriate opioid prescriptions.  
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INTRODUCTION 
Given that the risks of opioid therapy are becoming increasingly apparent, primary care 
physicians are under growing pressure to treat pain with non-opioid medications, particularly for 
certain patient populations. Comorbidities such as mental health disorders or a history of substance 
use disorders may place patients taking opioids at greater risk for opioid-related overdose or 
addiction (1). Yet non-opioid medications have their own risks, particularly among individuals with 
certain comorbidities and older adults (2, 3). Many individuals are unable to use opioid alternatives 
such as non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics due to comorbidities or 
concurrently prescribed medications (3).  
To date, however, it is not well understood how clinicians factor in patients’ comorbidities 
and concurrent prescriptions when prescribing opioids. Most studies examining opioid use have 
focused on patient risk factors associated with long-term opioid use, opioid overdose, or addiction 
such as mental health and substance use comorbidities; very few have examined patient 
comorbidities associated with contraindications of non-opioid analgesics (4, 5). Understanding how 
clinicians incorporate clinical comorbidities into decision-making around opioid prescribing can 
highlight potentially appropriate or inappropriate prescribing, focusing quality improvement efforts 
and improving the development of new, more nuanced quality measures (2).  
Our study objective was to examine whether patients with contraindications for non-opioid 
analgesics such as NSAIDs had higher odds of receiving an opioid prescription during an office visit 
for low back pain. We were also interested in whether patients with comorbidities or concurrent 
prescriptions that place them at higher risk for overdose or addiction had lower odds of receiving an 
opioid prescription. We selected to study patients with a low back diagnosis given that there is 
extensive literature documenting that opioids are often not recommended for this condition (6). 
METHODS 
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Study Setting, Population, and Retrospective Cohort Design 
Using administrative data, we created a retrospective cohort of patients with outpatient visits 
at a large, tertiary care academic health system and its associated primary care clinics. The health 
system is located in a metropolitan, urban area. Our population sample is primarily insured; most 
patients have private insurance or Medicare. In 2017, the last year of our study, 42% of the entire 
population of patients seen at primary and specialty care clinic visits at the medical center had 
Medicare as their primary payor, 5% had Medicaid, 49% had private insurance, and 3% had a payor 
classified as “other” (7). 
We included all patients with lower back pain diagnoses that had at least one office visit in 
any year between 2013-2017 and then extracted a year’s worth of retrospective data to identify 
factors associated with receipt of an opioid prescription made during the single primary care office 
visit. Our unit of analysis was the office visit.  
To construct the cohort, we first identified all outpatient office visits for low back pain from 
2013-2017 for all patients seen by clinicians affiliated with the health system and sampled the first 
office visit per patient per year. The office visit was defined as the first time that a patient had a non-
emergency, non-perioperative office visit with one of the selected ICD-9 codes identified for low 
back pain during each calendar year. We then restricted our sample to visits to primary care 
clinicians. For this visit, we extracted diagnoses, prescribed medications, and demographic data. We 
also extracted the following data from all visits during the 365 days prior to the visit: opioid 
prescriptions; prescriptions of anticoagulants, antiplatelets, or systemic steroids; NSAID 
prescriptions; diagnoses where NSAIDs are contraindicated; and diagnoses where opioids are 
contraindicated (see Appendices 2 and 3 for a list of specific diagnoses and ICD-9 codes). All data 
were extracted from a database (Clarity) with electronic health record (EHR) data of the academic 
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medical center using Structured Query Language (SQL). See Appendix 1 for a detailed description of 
the data extract. 
We excluded the following patient populations: patients under age 18 at the time of office 
visit, patients with a cancer diagnosis during the study period, patients pregnant during the sampled 
office visit, patients receiving palliative care, and individuals with vertebral fractures. These patients 
have specialized analgesic needs and we felt they fell outside the scope of this study as guidelines for 
opioid prescribing are very different for each group. We used ICD-9 codes (cross-walked with ICD-
10 codes in the database) for diagnostic data (See Appendix 1). Our final sample size was 21,020 
visits of patients with a low back pain diagnosis among 140 providers from 2013-2017.  
Conceptual Model 
We used a modified version of Raisch’s conceptual model of physician prescribing behavior 
to guide the selection of predictors and covariates (8, 9). In this model, prescribers are thought to be 
influenced by five categories of factors: patient clinical factors, patient sociodemographic factors, 
clinician factors, administrative and regulatory policies, and external factors. Patient clinical factors 
may include chronic pain diagnoses; risk factors for misuse, addiction, and overdose (e.g. diagnoses); 
condition and treatment history; pain and condition severity; and comorbidities associated with 
contraindications for non-opioid analgesics. Patient sociodemographic factors include patient race, 
ethnicity, age, gender, sex, and socioeconomic characteristics such as employment, education, and 
health literacy levels. Clinician factors include clinician age, gender, race, ethnicity, panel size, and 
clinician specialty. Administrative and regulatory policies, which Raisch and others call “direct 
factors,” include drug formularies; opioid prescribing restrictions at the local, state, or federal levels; 
organization protocols, organizational structure, and payment models (10). Organizational protocols 
may include protocols developed around using prescription database management programs 
(PDMPs), policies on how many opioids can be prescribed at any one visit, and quality improvement 
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initiatives aimed at monitoring opioid use at the clinic or physician level. Raisch also included a 
category of “indirect factors,” which he described as advertisements, pharmaceutical sales 
representatives, colleagues, medical school education, and continuing education programs in chronic 
pain or opioid prescribing. In the case of opioid prescribing, for example, there is ample literature on 
the effect of pharmaceutical firms’ efforts to promote opioid prescribing (11, 12).  
Some factors may explicitly influence prescribing, such as a patient’s diagnoses and 
comorbidities, and others might implicitly influence prescribing, such as a patient’s race or 
socioeconomic status. For example, studies have found that physicians are less likely to prescribe 
opioids to individuals of color due to potential implicit race bias (13). Some factors such as age 
might be both clinical factors and demographic factors, as clinicians might consider age in relation to 
an individual’s ability to metabolize medications (clinical factor) and also in implicitly perceiving that 
younger individuals might be more likely to misuse opioids (sociodemographic factor) (14).  
In this study, we focused on patient clinical and sociodemographic factors. While we were 
not able to model all factors associated with opioid prescribing decisions, since clinicians prescribing 
to individuals in our sample were all associated with one academic medical center, clinicians in our 
sample were often subject to similar organizational policies and protocols and the same legislative 
and regulatory factors.  
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Figure 1. Conceptual model of factors associated with prescribing decisions 
 
Measures 
Primary Outcome: Receipt of Opioid During Index Visit for Low Back Pain 
The primary outcome was defined as receipt of an opioid prescription during the primary 
care office visit for low back pain (yes/no). 
Comorbidities and Medication Use for Which Use of NSAIDs is Contraindicated 
One of our objectives was to examine visits where an opioid prescription was potentially 
appropriate, so we examined comorbidities where NSAIDs were contraindicated. We created 
separate indicators for the presence of comorbidities that have contraindications for NSAIDs, 
including kidney, liver, gastrointestinal, cardiovascular, and cerebrovascular diseases during the office 
visit or in the previous 365 days using ICD-9 codes (See Appendix 2 for a list of all of the codes 
used in this analysis).  
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Individuals may also be taking certain medications which may interact with NSAIDs or 
should not be prescribed concurrently due to gastrointestinal adverse effects (15-17). For these 
individuals, opioid medications may be the more appropriate choice for analgesia. These 
medications include long-term aspirin use, anticoagulant use, antiplatelet use, and long-term systemic 
steroid use. We used medications prescribed and ICD-9 codes for long-term use of these 
medications in the previous 365 days before the office visit to create indicators for each of these 
medications (Appendix 3).  
For certain conditions, anticoagulants, antiplatelets, and systemic steroids are often 
prescribed for long-term use (18-20). To avoid missing individuals taking these medications 
chronically (and thus who would be at risk for concurrent use with NSAIDs), we sought to capture 
patients on long-term use of these medications as well as those with concurrent use. We constructed 
categories of long-term use of these medications by counting the number of prescriptions before the 
office visit; if the patient had five or more prescriptions for one of these medication classes in the 
year prior to the office visit we analyzed, we defined that individual as having a long-term 
prescription. We created one combined indicator for long-term and concurrent anticoagulant and 
antiplatelet use and one combined indicator for long-term and concurrent systemic steroid use.  
Clinical Factors and Medication Use for Which Opioids are Contraindicated  
Tobacco use status and mental health diagnoses, including depression, anxiety, and 
substance use disorders, are risk factors for opioid use disorder and are thus considered relative 
contraindications for opioids (4, 21). We used ICD-9 codes previously identified in the literature to 
identify the presence of these diagnoses during the office visit and in encounters 365 days prior (22, 
23). We also examined concurrent benzodiazepine prescriptions, as benzodiazepine and opioid 
concurrent prescribing is contraindicated due to the high risk of overdose (24). We considered a 
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benzodiazepine to be concurrently prescribed if it was prescribed at the same office visit as the 
opioid.  
Previous Opioid Use 
We created several categories of previous opioid use documented in the EHR: no known 
opioid use prior to the office visit or no opioid use in the 45 days prior to the office visit; 
intermittent opioid use (use 45 days or fewer prior to the office visit but not on long-term opioids), 
and long-term opioid use (60 or more opioid days in the 90 days prior to the office visit) (25).  
Patient Sociodemographic Factors 
Following our conceptual model, we identified two categories of covariates: patient 
sociodemographic factors and patient clinical factors. Sociodemographic factors included age, sex, 
race, ethnicity, employment status, and marital status. Clinical factors also included long-term 
NSAID use, as we hypothesized that individuals prescribed NSAIDs for long periods of time would 
be less likely to be prescribed opioid medications as this would be their primary form of pain 
treatment.  
Analyses 
We used frequencies to examine univariate statistics. We used chi-square tests to examine 
associations between our independent and outcome variables. For our main analysis, estimated 
several logistic regressions. First, we estimated a model controlling for previous opioid use, using the 
three categories constructed above (no opioid use in the previous 45 days, intermittent opioid use, 
and long-term opioid use) (Model 1). We then estimated three models (Models 2-4) stratified by 
previous opioid use (25). To avoid overfitting the models, we included comorbidities and co-
prescriptions if the prevalence of the comorbidity or concurrent medication use was higher than 
1.5% in our sample. We controlled for the year of the prescription in all models. We used a 
generalized estimating equations approach to account for multiple visits for each patient over the 
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years and included robust standard errors to control for clustering of patients within physicians. We 
assumed an independent correlation matrix. We used the Stata margins command to estimate 
predicted probabilities.   
RESULTS 
Patient Sociodemographic Factors 
Patients received an opioid prescription at four percent of office visits for low back pain 
(865 of 21,020 visits) (Table 1). Nearly two-thirds of patients at the visits were female (60.8%). The 
majority of patients at the visits were non-Hispanic (78.8%). 59.6% of patients at the visits were 
White, 18.6% were Black, 11.2% were Asian/Pacific Islander, and 10.5% were of other racial 
background. Half of patients at the visits were married, in a domestic partnership, or had a 
significant other (51.3%). The majority of our sample was working (either employed full-time, part-
time, self-employed) or a full-time student (61.4%).   
Patient Sociodemographic Factors and Unadjusted Associations with Receipt of Opioid 
Prescription 
In the area of patient sociodemographic factors, the most notable associations were with 
regards to race and marital status. We found a significant association between race and receipt of an 
opioid at the primary care office visit. Of those individuals who received an opioid prescription at 
the office visit versus those who did not, higher proportions were Black individuals (26.6% versus 
18.3%). In contrast, while Asian/Pacific Islander patients made up 11.2% of the sample, 5.7% of 
patients receiving an opioid prescription were Asian/Pacific Islander. We also found a significant 
association between marital status and receipt of an opioid prescription at the office visit. Of those 
individuals who received an opioid at the visit versus those who did not, higher proportions were 
divorced, legally separated, or widowed (19.3% vs. 13.4%). 
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Prevalence of Comorbidities and Concurrent Medication Use for Which Use of NSAIDs are 
Contraindicated 
Among our sample, 69.9% of patients at visits had at least one comorbidity or long-term 
and/or concurrent prescription where NSAIDs were contraindicated. Relatively small proportions 
of our sample had kidney disease (5.8%) or liver disease (1.8%). Higher proportions had 
cardiovascular or cerebrovascular disease (9.6%) and gastrointestinal disorders (10.8%).  
We also examined the proportion of patients at the visits who were prescribed medications 
contraindicated with NSAIDs during the office visit or had long-term use of these medications.  
Nearly half of our sample (48.1%) was either prescribed a systemic steroid at the visit or had been 
prescribed 5 or more systemic steroid prescriptions in the previous 365 days prior to the visit. 
Anticoagulant and antiplatelet use was also high: 59.5% of individuals were taking these medications 
at the visit or were long-term users in the previous 365 days prior.  
Comorbidities and Concurrent Medication Use for Which Use of NSAIDs are 
Contraindicated and Unadjusted Associations with Receipt of Opioid Prescription 
Among the comorbidities, the only notable associations between a contraindication for 
NSAIDs and receipt of an opioid prescription during the visit were for kidney disease and 
cardiovascular or cerebrovascular disease. Of those who received an opioid prescription at the visit 
versus those who did not receive an opioid, higher proportions had kidney disease (10.1% versus 
5.6%) or cardiovascular/cerebrovascular disease (11.3% versus 9.5%). 
Noteworthy associations between medication use and prescription of an opioid at the visit 
included systemic steroid use and antiplatelet/anticoagulant use. Of those who received an opioid at 
the visit versus those who did not, higher proportions had concurrent or chronic systemic steroid 
use (48.7% versus 32.5%), and concurrent or long-term antiplatelet or anticoagulant use (60.2% 
versus 54.1%).  
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Comorbidities and Medication Use Associated with Relative Contraindications for Opioids 
Nearly one third of our sample (28.6%) had at least one comorbidity or concurrent 
medication associated with risk of opioid use disorder or overdose, relative contraindications for 
opioids. The prevalence of comorbidities associated with opioid use, opioid overdose, and opioid 
use disorder was relatively high in our sample. 10.3% of patients in our sample had a depression 
disorder diagnosis, 14.0% had an anxiety disorder diagnosis, and 6.2% had a substance use diagnosis. 
The majority of our sample had never used tobacco (69.9%) or had used tobacco and quit (21.8%). 
A small proportion were current tobacco users (8.3%). We found that 2.6% of patients were 
prescribed a benzodiazepine at the office visit.  
Comorbidities and Medication Use Associated with Relative Contraindications for Opioids 
and Unadjusted Associations with Receipt of Opioid Prescription  
A higher proportion of those who received an opioid during the visit had depression 
disorders (12.8% vs 10.2%), anxiety disorders (17.5% vs 13.9%), substance use disorders (12.9% vs 
5.9%), or received a prescription for a benzodiazepine during the visit (8% vs 2.4%). Of those who 
received an opioid at the visit versus those who did not receive an opioid, higher proportions were 
current smokers (12.9% vs 8.1%). 
Prior Opioid Use 
The majority of patients in our sample (93.2%) had no known opioid use 45 days prior to 
the visit. Approximately 5% were intermittent opioid users and 1.9% were long-term opioid users 
prior to the visit. 
Adjusted Odds Ratios Between Contraindications for NSAIDs and Receipt of Opioid 
Prescription 
As noted earlier, we estimated four separate logistic regression models (Table 5). Model 1 
included the full sample of visits for low back pain, adjusting for previous opioid use (N = 21,020). 
   71 
Models 2-4 were stratified according to opioid use prior to the office visit: no known opioid use 45 
days prior to the visit (N = 19,587), intermittent opioid use (N=1,042), or long-term opioid use 
(N=391).  
Adjusted Odds of Opioid Prescription and Sociodemographic Factors 
We found a modest positive association between patient sex and receipt of an opioid 
prescription at the visit among our full sample after controlling for previous opioid use, with males 
having higher odds of receiving an opioid prescription (Model 1, aOR: 1.18; 95% CI: 1.01-1.39) 
compared to females. We also found differences in the adjusted odds of receipt of an opioid 
prescription by race: compared to White patients, Black patients had 35% higher odds of receiving 
an opioid prescription across the full sample after controlling for prior opioid use (Model 1, aOR: 
1.35, 95% CI: 1.12-1.63), and 41% higher odds compared to White patients among those with no 
known opioid use 45 days prior to the visit (Model 2, aOR: 1.41, 95% CI: 1.14-1.74). 
Compared to White patients, Asian-American patients had 39% lower odds of receiving an 
opioid prescription across the full sample after controlling for prior opioid use (Model 1, aOR: 0.61, 
95% CI: 0.43-0.87) and 35% lower odds of receiving an opioid prescription if they had no known 
prior opioid use 45 days prior to the visit (Model 2, aOR: 0.65, 95% CI: 0.45-0.96).  
We also found that marital status was an important factor associated with receiving an opioid 
prescription during a primary care visit for low back pain. Compared to single patients, patients who 
were divorced, separated, or widowed had 50% higher odds of receiving an opioid prescription 
during the visit (Model 1, aOR: 1.50, 95% CI: 1.19-1.89). This association held for those with no 
known opioid use 45 days prior to the visit (Model 2, aOR: 1.53, 95% CI: 1.16-2.02), but not for 
those with intermittent or long-term opioid use. Among individuals who had intermittent opioid 
use, patients who were disabled or had never worked had 122% higher odds of receiving an opioid 
   72 
prescription than patients who were employed or full-time students (Model 3, aOR: 2.22, 95% CI: 
1.04-4.76).  
Adjusted Odds of Opioid Prescription and Comorbidities and Concurrent Medication Use 
for Which Use of NSAIDs is Contraindicated 
After adjusting for prior opioid use, we found that patients with kidney disease had 76% 
higher odds of receiving an opioid prescription during the visit, compared to patients with no kidney 
disease, after controlling for previous opioid use (Model 1, aOR: 1.76; 95% CI: 1.31-2.35). This 
translates to a difference in the predicted probability of receiving an opioid of 2.6% between 
individuals with kidney disease and individuals without kidney disease (6.6% vs. 4.0%). We report all 
predicted probabilities in Appendix Table 5. The same positive association and similar magnitude 
held for those with no known opioid use 45 days prior to the visit and those who had intermittent 
opioid use. Among long-term users, the association was of similar magnitude, but was not 
statistically significant.  
We also found that having a long-term or concurrent anticoagulant/antiplatelet prescription 
was associated with 41% higher odds of receiving an opioid prescription during the visit for the full 
sample, after controlling for previous opioid use (Model 1, aOR: 1.41, 95% CI: 1.18-1.90). This 
translates to a 1.3% difference in the predicted probability of receiving an opioid prescription 
between those with long-term or concurrent anticoagulant/antiplatelet use versus those without this 
type of medication use (4.4% vs. 3.7%). We found a similar positive association and magnitude for 
patients who had no prior opioid use 45 days to the visit and those with intermittent opioid use. 
Among long-term opioid users, having a concurrent or long-term anticoagulant/antiplatelet 
prescription was associated with 117% higher odds of receiving an opioid prescription at the visit 
(Model 4, aOR: 2.17, 95% CI: 1.17-4.02).  
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Other comorbidities or concurrent medications considered contraindications for NSAIDs 
— including having a diagnosis of liver disease, cardiovascular or cerebrovascular disease, or 
gastrointestinal disorders, or having a concurrent or long-term systemic steroid prescription — were 
not found to be associated with higher odds of receiving an opioid prescription during the visit in 
our models either controlling for previous opioid use or stratified by previous opioid use.  
Adjusted Odds of Opioid Prescription and Comorbidities and Medication Use Associated 
with Relative Contraindications for Opioids 
Having a history of or current substance use disorder was associated with 45% higher odds 
of receiving an opioid prescription at the office visit in the full sample after controlling for previous 
opioid use (Model 1, aOR: 1.45, 95% CI: 1.08-1.94). This translates to a 2.6% difference in the 
predicted probability of receiving an opioid prescription between those with a history of substance 
use disorder and those without such a history (6.6% vs. 4.0%). We found a similar magnitude of 
results among those with no opioid use 45 days prior to the visit (aOR: 1.65, 95% CI: 1.27-2.13). We 
also found that receiving a benzodiazepine prescription was positively associated with receiving an 
opioid prescription during the visit across all models, including the full sample after controlling for 
previous opioid use (Model 1, aOR: 3.22, 95% CI: 2.37,4.37). This translates to a 7.0% difference in 
the predicted probability of receiving an opioid prescription between those with a concurrent 
benzodiazepine prescription versus those without (10.89% vs. 4.0%). We had similar findings among 
patients with no known opioid use 45 days prior to the office visit (Model 2, aOR: 3.01, 95% CI: 
2.25-4.15), patients with previous intermittent opioid use (Model 3, aOR: 3.50, 95% CI: 1.27-9.90), 
and previous long-term use (Model 4, OR: 5.13, 95% CI: 1.76-14.97).  
We also found that tobacco use was positively associated with receipt of an opioid 
prescription at the visit in both our full sample and among those who had intermittent opioid use. 
Compared to never tobacco users, patients who were current tobacco users had 26% higher odds of 
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receiving an opioid prescription during the visit after controlling for previous opioid use (aOR: 1.26, 
95% CI: 1.07-1.48), and 79% higher odds among patients with intermittent prior opioid use (aOR: 
1.79, 95% CI: 1.21-2.65).   
DISCUSSION 
 In this retrospective cohort study of primary care visits of patients with low back pain, we 
examined comorbidities and concurrent prescriptions associated with both appropriate and 
inappropriate opioid prescribing, finding that clinicians did incorporate some important 
comorbidities and prescriptions when prescribing, including kidney disease, anticoagulant, and 
antiplatelet use, but missed or did not consider some important comorbidities and prescriptions 
associated with opioid overdose or addiction, including substance use disorder and concurrent 
benzodiazepine use.  
These are concerning findings because they illustrate that patients at higher risk for overdose 
or addiction might be receiving inappropriate opioid prescriptions. The risks of overdose and death 
increase significantly when patients are concurrently prescribed opioids and benzodiazepines (26, 
27). While patients with a history of substance use can still be prescribed opioids if followed closely 
(28), some patients can develop opioid use disorders when prescribed opioid medications (29). 
Individuals with mental health conditions are at significantly higher risk for substance use disorders 
overall, so avoiding unnecessary opioid prescriptions for these patients may be advised (1). Health 
systems and provider groups might consider additional training in opioid prescribing and academic 
detailing to help clinicians identify patients at highest risk for opioid overdose or misuse.  
Our findings also illustrated that clinicians are using patient comorbidities to make 
appropriate prescribing decisions. Various organizations and federal agencies are developing quality 
measures to examine prescribing at the system, facility, and provider levels (25, 30, 31). These 
measures are aimed at assisting health system leaders in identifying variation in prescribing levels 
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among clinicians in an effort to ultimately decrease initial opioid prescribing and long-term opioid 
use (25). However, an important limitation of these measures is that they do not distinguish between 
potentially inappropriate and potentially appropriate opioid prescribing. These quality measures may 
penalize clinicians, such as geriatricians, who treat a higher proportion of older patients with kidney 
disease or who are on anticoagulants or antiplatelet medications. Developing quality measures that 
incorporate patient comorbidities will more accurately capture appropriate and inappropriate 
prescribing.  
Our findings are in line with previous studies examining risk factors associated with opioid 
prescribing, addiction, and overdose. Others have found opioid prescriptions to be associated with 
nicotine use, depression, use of benzodiazepines, mood disorders, and history of substance use 
disorder (29, 32-34). Our findings regarding marital status and employment status are also in line 
with other studies, which found that divorced individuals and individuals on disability were more 
likely to be persistent opioid users (35). 
Our study has several limitations. Although we aimed to capture prior opioid use as 
accurately as possible, we may not have captured opioids prescribed outside of the health system. 
However, many prescribers enter recent or concurrent prescriptions into the EHR during the 
medication reconciliation portion of the visit, so we were able to capture prescriptions identified by 
the patient during the visit. We may also have missing diagnoses and medications for patients if they 
sought care outside of the system. However, we used data from visits 365 days prior to the visit, 
which improves our ability to identify diagnoses and long-term medication use. We also included an 
extensive list of comorbidities, many of which had not been explored in papers focused on opioid 
prescribing. There are also limitations inherent in using administrative data, including diagnoses or 
prescriptions that are noted by providers in free-text notes, which we were not able to include in this 
analysis. Finally, our study data was limited to one academic medical system with a predominantly 
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insured population in a large metropolitan area, so findings may not be generalizable to rural settings 
or low resource settings. 
In conclusion, our findings suggest that clinicians are considering some clinical comorbidities 
to make decisions about opioid prescribing for low back pain, including the presence of kidney 
disease and concurrent use of anticoagulants and antiplatelet medications, suggesting appropriate 
opioid prescribing. However, we also found that patients receiving a benzodiazepine prescription or 
with a history of substance use disorder had higher odds of receiving an opioid prescription, which 
indicates that some opioid prescriptions may place vulnerable patients at risk for overdose, 
addiction, or even death. Clinicians, pharmacists, and health system administrators should identify 
comorbidities and concurrent medication use during quality improvement initiatives to classify 
potentially appropriate and inappropriate opioid prescribing.  
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Table 1. Characteristics of Patients with Visits for Low Back Pain, 2013-2017, N=20,210   
  
No Opioid Receipt 
at Index Visit 
Opioid 
Receipt at 
Index Visit 
Total 
Sample 
P-Value 
   N (%)   N (%)   N   
     
 Total   20,155 (96)  865 (4)   21020 (100)   
 
Patient Demographic, Sociocultural, and Clinical Factors 
     
 Age       
 Under Age 65   14909 (74)   630 (72.8)   15539 (73.9)   
 Age 65 and Older   5246 (26)   235 (27.2)   5481 (26.1)  0.45 
 Sex       
 Female   12289 (61)   493 (57)   12782 (60.8)   
 Male   7866 (39)   372 (43)   8238 (39.2)  0.02 
 Hispanic Ethnicity       
 Non-Hispanic   15867 (78.7)   696 (80.5)   16563 (78.8)   
 Hispanic   3196 (15.9)   125 (14.5)   3321 (15.8)   
 Unknown/Refused   1092 (5.4)   44 (5.1)   1136 (5.4)  0.47 
 Race       
 White   12023 (59.7)   507 (58.6)   12530 (59.6)   
 Black   3690 (18.3)   230 (26.6)   3920 (18.6)   
 Asian/Pacific Islander   2305 (11.4)   49 (5.7)   2354 (11.2)   
 Other/Unknown   2137 (10.6)   79 (9.1)   2216 (10.5)  <0.001 
 Marital Status       
 Single   6344 (31.5)   250 (28.9)   6594 (31.4)   
 Married, Domestic Partnership, or Significant Other   10358 (51.4)   420 (48.6)   10778 (51.3)   
 Divorced, Legally Separated, or Widowed   2692 (13.4)   167 (19.3)   2859 (13.6)   
 Other/Unknown   761 (3.8)   28 (3.2)   789 (3.8)  <0.001 
 Employment Status       
 Full Time, Self-Employed, Part-Time, Full-Time Student   12391 (61.5)   508 (58.7)   12899 (61.4)   
 Retired   3758 (18.6)   175 (20.2)   3933 (18.7)   
 Disabled or Never Worked   951 (4.7)   60 (6.9)   1011 (4.8)   
 Not Employed, Unknown, or Missing   3055 (15.2)   122 (14.1)   3177 (15.1)  0.1 
 Index or Chronic NSAID Use       
 No   10136 (50.3)   571 (66)   10707 (50.9)   
 Yes   10019 (49.7)   294 (34)   10313 (49.1)  <0.001 
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Table 1, continued. 
Contraindications for NSAIDs 
No Opioid Receipt 
at Index Visit 
Opioid 
Receipt at 
Index Visit 
Total 
Sample 
P-Value 
  N (%)   N (%)   N   
 Kidney Disease       
 None   19030 (94.4)   778 (89.9)   19808 (94.2)   
 Diagnosed   1125 (5.6)   87 (10.1)   1212 (5.8)  <0.001 
 Liver Disease       
 None   19783 (98.2)   850 (98.3)   20633 (98.2)   
 Diagnosed   372 (1.8)   15 (1.7)   387 (1.8)  0.81 
 Cardiovascular or Cerebrovascular Disease       
 None   18241 (90.5)   767 (88.7)   19008 (90.4)   
 Diagnosed   1914 (9.5)   98 (11.3)   2012 (9.6)  0.07 
 Gastrointestinal Disorder, including GERD, Peptic Ulcers, or Bleeding   
 None   17972 (89.2)   774 (89.5)   18746 (89.2)   
 Diagnosed   2183 (10.8)   91 (10.5)   2274 (10.8)  0.77 
 Index or Chronic Systemic Steroid Use       
 No   10333 (51.3)   584 (67.5)   10917 (51.9)   
 Yes   9822 (48.7)   281 (32.5)   10103 (48.1)  <0.001 
 Index or Chronic Anticoagulant or Antiplatelet Use      
 No   8027 (39.8)   397 (45.9)   8424 (40.1)   
 Yes   12128 (60.2)   468 (54.1)   12596 (59.9)  <0.001 
     
Contraindications for Opioids 
     
 Depression Disorder       
 No   18101 (89.8)   754 (87.2)   18855 (89.7)   
 Yes   2054 (10.2)   111 (12.8)   2165 (10.3)  0.01 
 Anxiety Disorder       
 No   17357 (86.1)   714 (82.5)   18071 (86)   
 Yes   2798 (13.9)   151 (17.5)   2949 (14)  <0.01 
 Substance Use Disorder       
 No   18959 (94.1)   753 (87.1)   19712 (93.8)   
 Yes   1196 (5.9)   112 (12.9)   1308 (6.2)  <0.001 
 Benzodiazepine Prescribed at Index Visit       
 No   19674 (97.6)   796 (92)   20470 (97.4)   
 Yes   481 (2.4)   69 (8)   550 (2.6)  <0.001 
 Tobacco User       
 Never Smoker   14170 (70.3)   523 (60.5)   14693 (69.9)   
 Ever Smoker, Quit   4347 (21.6)   230 (26.6)   4577 (21.8)   
 Ever Smoker, Current   1638 (8.1)   112 (12.9)   1750 (8.3)  <0.001 
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Table 1, continued     
 
No Opioid Receipt 
at Index Visit 
Opioid 
Receipt at 
Index Visit 
Total 
Sample 
P-Value 
Opioid Use Prior to the Index Visit  N (%)   N (%)   N   
No Opioid Use 45 Days Prior to Index Visit 18,965 (96.8) 631 (3.2) 19,587 (93.2)  
Intermittent Opioid Use Prior to Index Visit  903 (86.7) 139 (13.3) 1,042 (4.96)  
Long-Term Opioid Use Prior to Index Visit 296 (75.7) 95 (24.3) 391 (1.86) <0.001 
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Table 2. Adjusted odds ratios between contraindications for NSAIDs and opioids and receipt of an opioid 
prescription at a primary care office visit for low back pain 
Outcome: Receipt of an opioid 
prescription at a primary care visit for 
low back pain. 
(1) (2) (3) (4) 
 Full Sample Opioid Naive Intermittent 
Opioid Use 
Long-Term Use 
     
Kidney Disease 1.758*** 
[1.308,2.364] 
1.686*** 
[1.240,2.294] 
1.998* 
[1.071,3.727] 
1.537 
[0.452,5.219] 
Liver Disease 0.744 
[0.462,1.198] 
0.696 
[0.334,1.448] 
0.529 
[0.0922,3.038] 
0.505 
[0.0852,2.989] 
Cardiovascular or Cerebrovascular 
Disease 
0.867 
[0.670,1.122] 
0.979 
[0.736,1.301] 
0.544 
[0.278,1.064] 
0.704 
[0.340,1.455] 
Gastrointestinal Disorder 0.801 
[0.631,1.018] 
0.831 
[0.619,1.115] 
0.758 
[0.435,1.320] 
0.579 
[0.229,1.464] 
Index or Chronic Steroid Prescription 0.623 
[0.379,1.026] 
0.519 
[0.260,1.035] 
0.545 
[0.217,1.365] 
0.865 
[0.343,2.180] 
Chronic NSAIDs Prescription 0.839 
[0.529,1.332] 
0.906 
[0.463,1.770] 
1.422 
[0.576,3.513] 
0.843 
[0.416,1.709] 
Index or Chronic Anticoagulant or 
Antiplatelet Prescription 
1.406*** 
[1.162,1.702] 
1.498*** 
[1.182,1.898] 
1.210 
[0.741,1.976] 
2.172* 
[1.172,4.023] 
Depression 0.929 
[0.731,1.180] 
0.956 
[0.748,1.222] 
1.023 
[0.590,1.773] 
1.187 
[0.504,2.797] 
Anxiety 0.820 
[0.671,1.001] 
0.889 
[0.683,1.158] 
0.463* 
[0.249,0.860] 
1.012 
[0.621,1.648] 
Substance Use 1.448* 
[1.081,1.941] 
1.645*** 
[1.272,2.128] 
0.954 
[0.428,2.125] 
1.112 
[0.532,2.325] 
Benzodiazepine Concurrently Prescribed 3.217*** 
[2.367,4.373] 
3.055*** 
[2.249,4.151] 
3.551* 
[1.274,9.898] 
5.126** 
[1.756,14.97] 
Age     
Under Age 65 -- -- -- -- 
Age 65 and Older 0.818 
[0.649,1.031] 
0.745* 
[0.582,0.954] 
1.055 
[0.520,2.141] 
0.868 
[0.356,2.116] 
Patient Sex     
Female -- -- -- -- 
Male 1.183* 
[1.011,1.384] 
1.153 
[0.986,1.350] 
1.108 
[0.768,1.598] 
1.536 
[0.898,2.625] 
Patient Race     
White -- -- -- -- 
Black 1.354** 
[1.122,1.634] 
1.405** 
[1.135,1.740] 
1.117 
[0.763,1.634] 
1.739 
[0.952,3.178] 
Asian/Pacific Islander 0.611** 
[0.428,0.873] 
0.652* 
[0.445,0.955] 
0.485 
[0.179,1.315] 
0.555 
[0.0333,9.249] 
Other 0.939 
[0.685,1.289] 
0.905 
[0.625,1.309] 
1.148 
[0.552,2.388] 
0.578 
[0.219,1.522] 
Patient Hispanic Ethnicity     
Non-Hispanic -- -- -- -- 
Hispanic 1.003 
[0.805,1.250] 
1.061 
[0.823,1.368] 
0.745 
[0.424,1.310] 
1.228 
[0.536,2.814] 
Unknown 1.123 
[0.803,1.570] 
1.035 
[0.705,1.518] 
1.601 
[0.471,5.444] 
1.234 
[0.301,5.057] 
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Table 2, continued     
Patient Marital Status     
Single -- -- -- -- 
Married/Domestic 
Partnership/Significant Other 
1.137 
[0.959,1.349] 
1.134 
[0.942,1.364] 
1.556 
[0.991,2.441] 
0.803 
[0.454,1.422] 
Divorced/Separated/Widowed 1.500*** 
[1.194,1.883] 
1.533** 
[1.162,2.023] 
1.527 
[0.940,2.479] 
1.097 
[0.415,2.901] 
Other/Unknown 1.158 
[0.756,1.773] 
0.961 
[0.545,1.696] 
1.666 
[0.574,4.840] 
20.31* 
[1.868,220.7] 
Patient Employment     
Employed or Full-Time Student -- -- -- -- 
Retired 0.950 
[0.697,1.295] 
1.007 
[0.732,1.386] 
1.112 
[0.506,2.442] 
0.593 
[0.210,1.676] 
Disabled/Never Worked 0.943 
[0.642,1.385] 
0.922 
[0.615,1.380] 
2.225* 
[1.041,4.755] 
0.204** 
[0.0711,0.583] 
Not Employed/Unknown 0.869 
[0.704,1.073] 
1.022 
[0.816,1.280] 
0.681 
[0.320,1.450] 
0.305 
[0.0831,1.116] 
Tobacco Use     
Never User -- -- -- -- 
Ever User, Current 1.256** 
[1.066,1.480] 
1.145 
[0.939,1.397] 
1.793** 
[1.212,2.652] 
1.333 
[0.702,2.530] 
Ever User, Quit 1.256 
[0.948,1.664] 
1.284 
[0.956,1.725] 
1.339 
[0.651,2.753] 
1.117 
[0.518,2.405] 
Opioid naïve Reference  
 
 
 
 
 
Intermittent Opioid Use 3.662*** 
[2.871,4.671] 
 
 
 
 
 
 
Long-Term Opioid Use 6.794*** 
[4.756,9.706] 
 
 
 
 
 
 
N 21020 19587 1042 391 
 
Exponentiated coefficients; 95% confidence intervals in brackets. Our models also controlled for the year of the  
visit.  
* p < 0.05, ** p < 0.01, *** p < 0.001 
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Appendix 1. Office Visit Extract Description 
 
Office Visit 
 
For the visit, we extracted medical record number (MRN), visit date, the visit encounter number, 
provider identification number, provider name, provider specialty, department name, birth date, sex, 
ethnic group, race, marital status, zip, employment status, most updated BMI, tobacco use. We 
dropped observations where the visit was for acupuncture, a dietitian, or where the provider 
specialty was missing. Since our aim was to capture opioid prescribing in the primary care setting, if 
the first visit for low back pain within that year occurred elsewhere (e.g., emergency department, 
inpatient, hospital outpatient, pre-operative and post-operative, infusion, or prenatal visit), we 
looked at the next office visit. If the patient had no eligible office visits during the calendar year, the 
individual was excluded from the analysis.  
 
Office Visit Opioid and Benzodiazepine Prescriptions 
 
Using the office visit prescription data, we created variable where at least one opioid was prescribed. 
We also created variable where at least one benzodiazepine was prescribed.  
 
Office Visit Inclusion and Exclusion Codes 
 
Below, we list the ICD-9 codes used as inclusion and exclusion criteria we used to create a cohort of 
patients for this retrospective observational cohort study.  
 
 
Appendix Table 1. Office Visit Low Back Pain Inclusion International Classification of Disease 
(ICD) 9 Codes and Descriptions 
ICD-9 Inclusion 
CodesICD-9 Code 
Description  
719.xx Joint Pain 
720.1 Enthesopathy, spinal 
720.2 Sacroiliitis NEC 
720.9 Spondylopathy, inflammatory NOS 
721.3 Spondylosis, lumbosacral 
721.42 Spondylosis, lumbar w/myelopathy 
721.6 Ankylosing vertebral hyperostosis 
721.7 Spondylopathy, traumatic 
721.8 Disorder, spinal NEC 
721.9 Spondylosis NOS 
721.9 Spondylosis NOS without myelopathy 
722 Disorders, intervertebral disc 
722.1 
Displacement of thoracic/lumbar intervertebral disc without 
myelopathy 
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722.1 
Displacement of thoracic or lumbar intervertebral disc without 
myelopathy 
722.2 
Displacement of intervertebral disc, site unspecified, without 
myelopathy 
722.32 Schmorl’s nodes, lumbar region 
722.5 Degeneration, thoracic/lumbar disc 
722.52 Degeneration, lumbar/lumbosacral disc 
722.6 Degeneration, disc NOS 
722.7 Intervertebral disc disorder with myelopathy 
722.7 Intervertebral disc disorder with myelopathy, unspecified region 
722.73 Intervertebral disc disorder with myelopathy, lumbar region 
722.8 Postlaminectomy syndrome 
722.83 Syndrome, postlaminectomy, lumbar 
722.9 Disorder, intervertebral disc, other and unspecified 
722.9 Disorder NEC/NOS, unspecified disc 
722.93 Disorder NEC/NOS, lumbar disc 
724 Stenosis, spinal, other than cervical 
724 Stenosis, spinal, unspecified region 
724 Disorders, back, other and unspecified 
724.02 Stenosis, spinal, lumbar 
724.09 Stenosis, spinal, other 
724.1 Pain in thoracic spine 
724.2 Lumbago 
724.3 Sciatica 
724.4 Neuritis, lumbosacral NOS 
724.5 Backache NOS 
724.6 Disorders, sacrum (including lumbosacral joint instability) 
724.7 Disorders, coccyx 
724.71 Hypermobility, coccyx 
724.79 Disorder, coccyx NEC 
724.8 Symptom, back NEC 
724.9 Disorder, back NOS 
728.2 Atrophy, muscular disuse NEC 
728.8 Disorders, muscle/ligament/fascia 
728.85 Spasm, muscle 
728.9 Disorder, muscle/ligament NOS 
729.1 Myalgia/myositis NOS 
729.2 Neuralgia/neuritis NOS 
729.9 Disorder, soft tissue NEC/NOS 
733.13 Pathologic fracture of vertebrae 
737.3 Kyphoscoliosis and scoliosis 
737.3 Scoliosis, idiopathic 
737.39 Scoliosis NEC 
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738.4 Spondylolisthesis, acquired 
738.5 Deformity, acquired, back/spine NEC 
739.3 Lesion, nonallopathic, lumbar region 
739.4 Lesion, nonallopathic, sacral region 
756.1 Anomaly, congenital, spine 
756.1 Anomaly, congenital, spine NOS 
756.11 Spondylolysis, congenital, lumbosacral 
756.12 Spondylolisthesis, congenital 
756.15 Fusion, spine, congenital 
793.7 Nonspecific abnormal radiological finding, musculoskeletal system 
799.8 Condition, ill-defined NEC 
839.2 Dislocation, thoracic/lumbar vertebra, closed 
839.2 Dislocation of lumbar vertebra, closed 
839.42 Dislocation, sacrum, closed 
839.69 Dislocation site NEC, closed 
839.8 Dislocation, multiple and ill-defined, closed 
846 Sprain/strain, sacroiliac region 
846 Sprain/strain, lumbosacral 
846.1 Sprain/strain, sacroiliac ligament 
846.2 Sprain/strain, sacrospinatus 
846.3 Sprain/strain, sacrotuberous 
846.8 Sprain/strain, sacroiliac site NEC 
846.9 Sprain/strain, sacroiliac site NOS 
847 Sprains/strain other/unspecified parts back 
847.2 Sprain/strain, lumbar region 
847.3 Sprain/strain, sacrum 
847.4 Sprain/strain, coccyx 
847.9 Sprain/strain, back NOS 
848.8 Sprain/strain NEC 
848.9 Sprain/strain NOS 
905.7 Late effect, sprain/strain 
922.3 Contusion, back 
922.31 Contusion, back 
922.32 Contusion, buttock 
922.9 Contusion, trunk NOS 
953.2 Injury, lumbar root 
953.5 Injury lumbosacral plexus 
956 Injury sciatic nerve 
959.1 Injury NOS, trunk 
959.19 Injury NOS, other sites trunk 
  
ICD-9 Exclusion 
Codes Description 
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 (140.0-239.9) OR 
(338.3);  Patients with a cancer diagnosis during study period, ICD-9 codes 
(V667) 
Patients receiving palliative care administered 6 months prior to the 
study period or during the study period  
324.1 Intraspinal abscess 
730 Osteomyelitis 
805.1 Open vertebral fractures 
805.3 Open vertebral fractures 
805.5 Open vertebral fractures 
805.7 Open vertebral fractures 
805.9 Open vertebral fractures 
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Appendix 2: Comorbidities and Prescriptions from Office Visit and Visits 365 Days Prior 
 
Below, we list the ICD-9 codes we used to categorize diagnoses during the primary care office visit 
and from all visits recorded in the electronic health record 365 days prior.  
 
Appendix Table 2. ICD-9 Codes Used to Create Comorbidity and Chronic Prescription Data at the 
Office Visit and From Visits 365 Days Prior  
ICD-9 Code Description 
GI Conditions  
530, 531, 578 Gastroesophageal reflux disease (530), Gastrointestinal ulcer (531), 
Gastrointestinal bleeding (578) 
Kidney Conditions  
584, 585, 584* 585* 586* 593* 
403* V4511 V4512 V56* 
kidney disease (585), renal failure (586), unspecified kidney disease 
(593), hypertensive chronic kidney disease (403), dialysis 
Inflammatory Bowel 
Disease 
 
555*, 556* Crohn’s Disease (555), UC (556) 
Liver Conditions  
571* Liver Disease (571) 
Gastric bypass or 
gastroplasty 
 
V45.86 Bariatric surgery status (V45.86) 
Pregnancy  
V22* Pregnancy (V22*) 
Cardiovascular disease  
410* 411* 412* 413* 414* 
428* 430* 431* 432* 433* 
434* 435* 436* 437* 438* 
443.9 433.10 440.9 
acute myocardial infarction 410 
other acute and subacute forms of ischemic heart disease 411 
intermediate coronary syndrome 411.1 
old myocardial infarction 412 
angina* 413.0 
coronary atherosclerosis 414.00 
Congestive heart failure, unspecified 428.0 
Cerebrovascular Disease 430-438 
Peripheral vascular disease, unspecified 443.9 
Occlusion and stenosis of carotid artery without 
mention of cerebral infarction 433.10 
Generalized and unspecified atherosclerosis 440.9 
Long-Term Use of Aspirin  
V5869 Long-term aspirin use 
Long-Term Anticoagulant 
Use 
 
V5862 Long-term anticoagulant use 
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Appendix 3. Office Visit and Prior Visit Medication Use 
 
We used two sources of medication data to create the indicators in our final models. We used 
prescriptions from 365 days prior to the office visit and medications concurrently prescribed at the 
visit. We excluded medications labeled “suspend.” We included medications that were not ordered 
but entered into the chart as “provider historical,” as these were entered in the record during the 
medication reconciliation.  
 
Appendix Table 3. Medication Classes Used to Identify Medications Concurrently Prescribed During 
the Office visit and from Outpatient Visits 365 Days Prior 
Medication Class Examples 
NSAIDs Ibuprofen, celecoxib 
Antiplatelets Clopidogrel, ticagrelor 
Anticoagulants Heparin, warfarin 
Systemic Corticosteroids Prednisone, prednisolone 
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Appendix 4. Opioid Prescription Calculation Assumptions 
  
Data Source 
To construct a master list of opioid medications, we used the Centers for Disease Control and 
Prevention (CDC) Opioid Data Files, which contain morphine equivalent conversion factors 
(MECF), the strength per medication unit, and a National Drug Code for non-IV opioid 
medications based on formulation [13 15]. For methadone, the CDC table provides a morphine 
equivalency for the lowest dose. However, methadone’s morphine equivalency must be adjusted 
based on the total daily dose: the higher the daily dose, the higher the conversion factor. We 
developed logic to calculate the daily dose and then applied the appropriate conversion factor. For 
buprenorphine films, we used a regular expression to extract the strength per unit from the 
medication name and assigned a morphine equivalency conversion factor of 12.6 based on Centers 
for Medicare & Medicaid Services (CMS) conversion factors [16].  
  
Medication data for each of the cohorts was extracted from the Clarity database, including the 
prescription Sig (i.e. the prescription administration instructions), quantity prescribed, units per dose, 
doses per day, start date of the prescription, and the authorizing provider. To calculate the opioid 
use prior to the visit, we included all outpatient opioid prescriptions, either discharge medications 
from an inpatient stay, an emergency department (ED) visit, or any ambulatory setting. We excluded 
intravenous (IV) medications from our analysis. We also excluded medications that were 
discontinued within 3 days of ordering, which we assumed had been ordered in error and then 
cancelled. 
  
Calculating Days’ Supply 
The days’ supply for the opioid prescription was calculated using the formula below:   
  
 
We used this formula to calculate the number of days for each prescription, which was then used to 
create the categories of pre-visit opioid use: 
 
1. No known opioid use in 45 days prior to the visit; 
2. Intermittent opioid use, or opioid use 45 days or fewer prior to the visit but not on long-
term opioids; 
3. Long-term opioid use, or 60 or more opioid days in the 90 days prior to the visit) (25).  
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Appendix 5. Table 4. Adjusted Predicted Probabilities of Contraindications for NSAIDs and Opioids and 
Receipt of an Opioid at a Primary Care Office Visit for Low Back Pain 
 
 
Predicted  
Probability 
Marginal  
Difference 
[95%  
Confidence  
Intervals] 
Kidney Disease     
None 0.04   0.03 0.05 
Diagnosed 0.07 0.03 0.05 0.08 
Liver Disease     
None 0.04   0.04 0.05 
Diagnosed 0.03 -0.01 0.02 0.05 
Cardiovascular or Cerebrovascular Disease   
None 0.04   0.04 0.05 
Diagnosed 0.04 -0.01 0.03 0.05 
Gastrointestinal Disorder, including GERD, Peptic Ulcers,  
or Bleeding 
None 0.04   0.04 0.05 
Diagnosed 0.03 -0.01 0.03 0.04 
Index or Chronic Systemic Steroid Use   
No 0.05   0.04 0.06 
Yes 0.03 -0.02 0.02 0.04 
Index or Chronic NSAID Use    
No 0.04   0.03 0.05 
Yes 0.04 -0.01 0.03 0.05 
Index or Chronic Anticoagulant or Antiplatelet Use  
No 0.04  0.03 0.04 
Yes 0.05 0.01 0.04 0.06 
Depression Disorder    
No 0.04   0.04 0.05 
Yes 0.04 0.00 0.03 0.05 
Anxiety Disorder     
No 0.04   0.04 0.05 
Yes 0.04 -0.01 0.03 0.04 
Substance Use Disorder    
No 0.04   0.03 0.05 
Yes 0.07 0.02 0.04 0.07 
Benzodiazepine Prescribed at Index Visit   
No 0.04   0.03 0.04 
Yes 0.11 0.07 0.08 0.14 
Age     
Under Age 65 0.04 Reference 0.04 0.05 
Age 65 and Older 0.04 -0.01 0.03 0.04 
Sex     
Female 0.04 Reference 0.03 0.04 
Male 0.05 0.01 0.04 0.05 
Hispanic Ethnicity     
Non-Hispanic 0.04 Reference 0.03 0.05 
Hispanic 0.05 0.01 0.04 0.06 
Unknown/Refused 0.03 -0.01 0.02 0.03 
Race 0.04  0.00 0.03 0.05 
White  Reference   
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Black 0.04 0.00 0.03 0.05 
Asian/Pacific Islander 0.04   0.00 0.03 0.05 
Other/Unknown 0.05  0.01 0.03 0.06 
Marital Status     
Single 0.04 Reference 0.03 0.04 
Married, Domestic Partnership, or Significant Other 0.04 0.00 0.03 0.05 
Divorced, Legally Separated, or Widowed 0.05 0.02 0.04 0.06 
Other/Unknown 0.04 0.01 0.02 0.06 
Employment Status     
Full Time, Self-Employed, Part-Time, Full-Time Student 0.04 Reference 0.04 0.05 
Retired 0.04 0.00 0.03 0.05 
Disabled or Never Worked 0.04 0.00 0.03 0.05 
Not Employed, Unknown, or Missing 0.04 -0.01 0.03 0.05 
Tobacco User     
Never Smoker 0.04 Reference 0.03 0.04 
Ever Smoker, Quit 0.05 0.01 0.04 0.05 
Ever Smoker, Current 0.05 0.01 0.03 0.06 
Opioid Use Before     
No opioid use 45 days prior  0.03 Reference 0.03 0.04 
Intermittent Opioid Use 0.11 0.08 0.09 0.13 
Long-Term Opioid Use 0.18 0.15 0.13 0.23 
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DISCUSSION 
 The three studies in this dissertation aimed to capture various decision-making challenges 
faced by clinicians prescribing opioids in outpatient settings in the midst of an important public 
health crisis. Opioid-related overdoses continue to rise, and although many are now driven by illicit 
fentanyl and other drugs, prescription opioid overdoses continue to be a major public health 
challenge (3). Against this backdrop of opioid overdoses and stricter regulations around opioid 
prescribing, clinicians must continue to form and maintain relationships with their patients and 
effectively treat and manage patients’ painful conditions. In this dissertation, I focused on three 
decision-making points faced by clinicians who prescribe opioids: how to assess whether patients are 
misusing or abusing opioids, whether to assume a new patient’s existing opioid prescription, and 
how to balance prescribing opioids for patients who may have few options for pain control given 
other medical conditions or concurrent prescriptions.  
In the first study, I examined how clinicians are contending with whether and how to 
implement four opioid risk mitigation strategies in their clinical practices. For certain clinicians, 
particularly those focused on episodic care, we found that the strategies helped clinicians set limits 
with patients and document misuse or abuse using objective evidence. Organizational policies and 
protocols not only made use of the strategies seamless, it also gave clinicians the ability to blame an 
outside entity – “the government” or “our center” – for their use, thus depersonalizing the use of 
these potentially disruptive strategies. Other clinicians, specifically clinicians for whom developing 
long-term, trusting relationships is important, found the strategies disruptive to their relationships 
and unfair to patients. These findings demonstrate that policies should consider the nature of the 
patient-clinician relationship when creating and implementing strategies to reduce opioid misuse or 
abuse. Strategies tailored to different settings or implementation approaches that take these 
relationships into account may be more successful.  
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 In the second study, I analyzed how clinicians make decisions about refilling and managing a 
new patient’s existing opioid prescriptions. Using a sample of clinicians affiliated with a tertiary care 
medical center, I found that clinicians took three different approaches to assuming a new patient’s 
opioid prescriptions. Clinicians in the Staunch Opposers group were highly averse to assuming new 
patients’ existing opioid prescriptions. These clinicians perceived opioids as inappropriate for 
chronic pain and used pre-screening approaches to avoid seeing patients who might be asking for 
the continuation of their opioid prescriptions. Clinicians in the Cautious and Conflicted group were 
apprehensive about assuming a new patient’s opioid prescriptions and generally only agreed if they 
deemed the patient to be trustworthy. These clinicians also only continued the opioid prescription if 
the opioid medication fell within their comfort zone with regards to daily dose and type of opioid. 
Clinicians in these first two groups often felt resentful that other clinicians “dumped” patients with 
existing opioid prescriptions on them. Finally, clinicians in the Rapport Builders group worked to 
establish trusting relationships with patients before collaborating with patients to taper down 
prescriptions. Findings from this study touch on the marginalization of patients taking opioids or 
developing substance use disorder. As opioid prescribing becomes increasingly scrutinized, many 
clinicians may feel uncomfortable with prescribing opioids and continuing prescriptions they did not 
start, particularly if the prescriptions are for higher doses or higher potency medications. As this 
study found, and others have noted (7-9), this apprehension could lead clinicians to stop prescribing 
opioids or avoid assuming prescriptions for patients on existing long-term opioid therapy, with 
concerning consequences for patients. 
In the last paper, I sampled primary care visits for low back pain from 2013-2017 within one 
health system and examined whether individuals were prescribed an opioid during this visit based on 
having comorbidities or concurrent prescriptions known to be contraindications for NSAIDs or 
relative contraindications to opioids. After controlling for previous opioid use, I found that patients 
  97 
with kidney disease, a significant contraindication for NSAIDs, had higher odds of receiving an 
opioid prescription. This finding indicates potentially appropriate opioid prescribing. However, I 
also found that patients with a history of substance use or a concurrent benzodiazepine prescription 
had higher odds of receiving an opioid prescription compared to individuals without either. These 
findings indicate that clinicians may be writing potentially inappropriate opioid prescriptions, placing 
patients at higher risk for overdose or addiction.   
Barriers to improving opioid prescribing 
The decision-making processes examined in these studies are complex and how clinicians 
approach each decision-making point can have significant consequences for patients. For example, if 
clinicians perceive that using the risk strategies is too onerous and decide not to prescribe any 
opioids, patients with existing opioid prescriptions or with few analgesic alternatives due to 
comorbidities may have a difficult time accessing high-quality care. On the other hand, if clinicians 
ignore the use of all risk mitigation strategies and prescribe opioids to patients with a previous 
history of substance use, they may place patients at higher risk for developing opioid use disorder. 
However, thoughtful, complex decision-making takes time and resources. As the authors of the 
2016 CDC guidelines note in a 2019 commentary reflecting on the guidelines, “there are no 
shortcuts to safer opioid prescribing” (8). The three studies in this dissertation demonstrate that 
there are two significant barriers to improving care for individuals who are prescribed opioids: 
internalized stigma among providers towards patients on long-term opioid therapy or who have 
developed substance use and a lack of incentives within the health system to manage opioid 
prescriptions safely and appropriately. 
Findings from the two qualitative studies illustrate that many clinicians are uncomfortable 
with patients exhibiting potential first signs of substance use disorder, and in the third study, I found 
that patients with a history of substance use disorder had a higher probability of receiving an opioid 
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than those without such a history. In the first study, Non-adopters of risk mitigation strategies such 
as urine drug testing and the opioid contract reported that rather than using these strategies with 
patients whom they felt misused opioids – often a sign of potential incipient substance use disorder 
–  they referred the patient out to another provider. In the second study, two groups of clinicians, 
the Staunch Opposers and the Cautious and Conflicted Clinicians, were apprehensive about or 
outright averse to assuming a new patient’s opioid prescriptions. While in many cases this may 
reflect discomfort with continuing the previous therapy, providers may also be uneasy about 
managing prescriptions for patients who may have undiagnosed substance use disorders. These 
findings reflect other studies which have found that many clinicians are wary of managing patients 
with potential or diagnosed substance use disorders (10, 11). Clinicians report having little training 
on substance use disorder management and find it difficult to discuss drug use with patients (12). 
Additionally, many clinicians may not yet accept the biopsychosocial model of addiction, which sees 
addiction as a biological disease rather than a moral or social failing (11). Increasing substance use 
training in medical schools and in continuing education programs may decrease stigma and increase 
clinicians’ self-efficacy with regards to treating patients with substance use disorders.  
Another important barrier to safe and appropriate opioid prescribing is the lack of incentives 
for this type of care in the current health care system. Conversations with patients about safe opioid 
use may require longer visits. Making decisions about whether to prescribe opioids may require 
complex decision-making about a patient’s comorbidities and risk factors, which may necessitate 
difficult discussions about prior and current substance use. Using risk mitigation strategies such as 
the state databases on controlled substances or urine drug testing may unearth findings that demand 
thoughtful conversations about addiction treatment. All of these conversations take time, and in a 
system that prioritizes efficiency and short visits, it may be difficult for clinicians and patients to 
broach these difficult topics.   
  99 
Building on the Model of Methods for Influencing Prescribing 
Findings from this dissertation advance the science on decision-making around prescribing 
by identifying important factors and processes associated with prescribing not previously described 
in the literature. Previous reviews of factors and models associated with prescribing include one 
developed by Raisch, who developed a Model of Methods for Influencing Prescribing (MMIP) (13, 
14). Raisch reviewed four sources of literature to identify factors that influence prescribing, 
including: (1) theoretical models of prescribing, (2) theories of persuasion, (3) the literature around 
interventions (educational and policy-related) aimed at improving prescribing, and (4) theories about 
decision-making (13, 14). Factors posited to influence prescribing in the MMIP include patient 
characteristics (symptoms, diagnoses, and psychosocial factors); clinician characteristics (race, 
gender, socioeconomic class, and training); and organizational factors (prescribing restrictions, 
protocols, financial incentives, and formularies). The MMIP also theorizes that clinicians’ 
prescribing intentions are formed by internal decision-making processes that incorporate attitudes 
towards the drugs, subjective norms about prescribing and biases including heuristics (cognitive 
shortcuts) that can make prescribing more pragmatic but potentially less optimal. Heuristics, 
developed in the psychology literature (15), include representativeness, availability, framing, and 
anchoring heuristics. For instance, a representative heuristic involves making decisions based on the 
perceived similarity of certain events; an availability heuristic involves making decisions based on 
vivid or recent experiences; and an anchoring heuristic explains how individuals are highly 
influenced by initial judgements or decisions (16, 17). The internal decision-making process is also 
shaped by a variety of external influential factors such as advertisements, pharmaceutical 
representative visits, continuing education, and colleagues. Finally, the MMIP includes a construct 
around how feedback about previous therapy can shape perceptions about the diagnosis and 
prescribing decisions. 
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In this dissertation, I found several ways in which decision-making around prescribing of 
opioids corresponds to existing constructs within the MMIP. In Study 1, adopters of the risk 
mitigation strategies discussed organizational protocols, legislative policies, and the CDC guidelines 
with patients. These findings map onto the upstream organizational factors described in the MMIP. 
In Study 2, I found that clinicians mentioned subjective norms around prescribing set by colleagues 
and administrators; e.g., describing clinicians in one clinic as being all “no opioid” or “low opioid” 
prescribers. These subjective norms, described in the MMIP, play a role in the internal decision-
making process and have also been found by others to be influential in prescribing decisions (18). I 
also found that heuristics are often used by clinicians when making decisions around prescribing. In 
Study 1, when making decisions about whether and when to use the risk mitigation strategies, we 
found that clinicians’ vivid experiences about patients becoming upset when the opioid contract was 
introduced influenced non-adoption of this strategy. In Study 2, when making decisions about 
whether to take on new patients on existing opioid prescriptions, clinicians whom we identified as 
Staunch Opposers often described patients on chronic opioid therapy in a negative light, using 
descriptors such as “drug addicts,” even when some patients may have been on these medications 
appropriately, as indicated by the findings of Study 3. Making generalized judgements about patients 
based on little information is an example of the representativeness heuristic. In Study 2, clinicians 
described relying on markers of trustworthiness, such as accepting new patients only from trusted 
referring clinicians, also an example of the use of heuristics. These findings illustrate that the MMIP 
effectively captures different constructs associated with decision-making for prescribing opioids. 
However, I also found ways in which the findings from this dissertation expand and extend 
the MMIP. I identified several new constructs that may influence prescribing, including (1) the 
nature of the patient-clinician relationship, (2) the management of risks to both the patient and 
clinician, (3) ethical considerations, and (4) perceptions relating to the prescriber’s identity and role 
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as a clinician. Additionally, while the MMIP is useful for conceptualizing a single prescribing 
episode, decision-making around prescribing has become increasingly complex given the rise in 
prevalence of chronic diseases and the corresponding long-term pharmacological therapies to 
manage these conditions. Clinicians often make recurring prescribing decisions over time while 
working within our fragmented healthcare system; (5) I consider this longitudinal perspective in an 
expansion of the model. 
Based on findings from this dissertation and other studies, I argue that the nature of the patient-
clinician relationship significantly influences prescribing decisions and thus is an important construct 
that should be added to the MMIP. In Study 1, I found that in settings where clinicians often 
developed long-term relationships with patients, such as primary care or rheumatology clinics, 
clinicians were much less likely to adopt the risk mitigation strategies when prescribing opioids. 
These providers expressed that their existing knowledge of their patients made use of the strategies 
unnecessary, uncomfortable, and disruptive to the patient-clinician relationship. In Study 2, I also 
found that willingness to take on patients already on chronic opioid medications was reliant on trust-
building in order to transition patients to safer doses of opioids. Maintaining a trusting patient-
clinician relationship has been identified as one of the most important factors driving general 
prescribing decision-making (19, 20) further underscoring the importance of adding this to the 
MMIP. Similar to findings in Study 1, one qualitative study found that patients who were well-
known to the physician were afforded more flexibility when requesting medications and were more 
likely to be granted controlled prescriptions without an in-person visit (21). The nature of the 
patient-clinician relationship likely influences the internal decision-making process described by the 
MMIP, and future research should expand on how the nature of these relationships influence 
appropriate or inappropriate prescribing decisions. 
  102 
Managing various types of risks was also an important consideration: when prescribing 
medication (particularly those with high risk of abuse or misuse) clinicians consider potential risks to 
the patient, identify strategies to assess risks, select which strategies to use, interpret and act on the 
information, and then make appropriate decisions around prescribing. In Study 1, I identified how 
clinicians who adopted and did not adopt the various risk mitigation strategies assessed risk of abuse 
or misuse. For example, clinicians who did not adopt the risk mitigation strategies still found ways to 
assess a patient’s risk for misuse such as requesting previous records or looking for suspicious 
behaviors. Clinicians must also think about risks of adverse effects and drug-drug interactions. In 
Study 3, I found that clinicians balanced risks of existing comorbidities and concurrent prescriptions 
when making prescribing decisions: individuals who were unable to tolerate non-opioid alternatives 
due to kidney disease or concurrent anticoagulants or antiplatelet medication use were more likely to 
receive an opioid prescription at a visit for low back pain. However, I also found that patients with a 
history of substance use disorder or concurrently receiving a benzodiazepine were also much more 
likely to receive an opioid prescription, placing these patients at greater risk for opioid use disorder 
or overdose. These findings suggest that clinicians may be more likely to act on certain risks over 
others. Future research should seek to elucidate how clinicians balance various types of risks. 
Clinicians must also consider professional risks to themselves, such as potentially prescribing to an 
individual who is diverting medications or prescribing to an individual who may experience a fatal 
overdose from medications. In either case, clinicians could face serious professional sanctions or 
lose their license to practice as has been seen in recent years (22, 23). Coverage of these arrests and 
of the overall opioid epidemic have resulted in clinicians feeling anxious about risks to their 
professional livelihoods. In Study 2, I found that many clinicians were conflicted and cautious about 
prescribing opioids, and several expressed that they either didn’t prescribe any opioids or were 
planning on not prescribing opioids in the future. These decisions likely reflect a desire to reduce 
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professional risks associated with certain prescribing scenarios, such as prescribing high-dose or 
high-potency opioids. Thus, findings from these studies argue for including constructs related to risk 
management in the MMIP. 
Clinicians also reflected on ethical considerations when making decisions about prescribing and 
adopting the use of risk mitigation strategies. In Study 1, I found that clinicians considered 
perceptions of whether the strategies benefitted the patient, invoking the ethical principle of 
beneficence. Clinicians also considered fairness, bearing in mind whether the strategies treated 
patients equally, and autonomy, reflecting on whether the strategies shifted too much power to the 
physician. In Study 2, providers in the Rapport Builders group also expressed ethical considerations, 
noting that it would be unethical to refuse refills to new patient on existing opioid medications 
because the patient could end up with an unscrupulous provider who didn’t manage opioids 
properly. Given these findings, including ethical considerations in the MMIP more closely models 
real-world prescribing. 
Findings from this dissertation also touch upon how clinicians may see themselves in their 
professional roles. One study found that clinicians tend to identify primarily with one role: a healer, a 
businessperson, a researcher, a clinical expert, or a teacher. These self-identified roles may influence 
prescribing behavior (24). In Study 2 for example, we found that some clinicians saw themselves as 
clinical experts and preferred to provide tertiary care exclusively, while others prided themselves on 
developing continuous, long-term care to patients. These self-defined roles influenced prescribing, 
as clinicians who defined themselves as clinical experts did not want to assume a patient’s chronic 
opioid prescriptions, while those who valued longitudinal care were more open to managing long-
term prescriptions. Other studies have found similar findings, noting that prescribing behavior is 
often driven by provider characteristics and self-identity. In one qualitative study focused on general 
prescribing in the primary care setting, clinicians were divided into high, medium, and low-cost 
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prescribers based on their prescribing behaviors. High-cost prescribers tended to be driven by “an 
aggressive desire to find out what the patient’s problem was and to ‘fix’ it” (25). High-cost 
prescribers also tended to see the medical visit as a business transaction and had a more difficult 
time saying no to patients. In contrast, low-cost prescribers tended not to view pharmaceuticals as 
the answer for all health problems. More research is needed to understand how clinicians self-
identify and how these self-identified roles may lead clinicians to adopt different prescribing and 
treatment approaches.  
Originally developed in 1990, the MMIP may be limited in its current applicability given the 
nature of how chronic diseases are managed today and how the healthcare system has evolved. 
Approximately 40% of Americans now manage multiple chronic conditions (26). These individuals 
often see multiple clinicians for treatment including many specialists (27); and are prescribed many 
medications, increasing the risk of drug-drug interactions and adverse effects (28). Thus, prescribing 
decisions today may involve piecing together a patient’s complex medical history of various 
diagnoses, prescriptions, procedures, imaging tests, and laboratory results from different clinicians 
over multiple visits. The fragmentation of the healthcare system further increases the complexity of 
this decision-making process, as the information may not be easily accessible from the electronic 
health care record given the lack of connectivity between different systems. 
I therefore argue for an expansion of the MMIP that considers how a clinician and patient 
may have recurring interactions over time and interactions with multiple clinicians of different 
specialties. As a result of these two factors, clinicians face frequently changing prescribing decisions. 
For example, for patients with chronic conditions such as chronic pain, prescribing decisions may 
change based on a patient’s evolving comorbidities, concurrent prescriptions, and risks for misuse or 
abuse. As patients age, risk-benefit calculations may shift as age is a risk factor associated with opioid 
misuse and abuse: younger individuals are at highest risk for misuse or abuse of opioids and the risk 
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of abuse or misuse decreases considerably with increasing age (29). Furthermore, aging patients may 
develop other types of conditions contraindicated with non-opioid analgesics, such as kidney, 
cardiovascular, gastrointestinal, cerebrovascular and other diseases, and thus opioids may become 
more attractive options, as I found in Study 3. An expanded MMIP that incorporates the evolving 
decision-making process over repeated interactions would more closely capture prescribing decisions 
in our current health care environment. 
Findings from Study 2 also highlight another important element missing in the MMIP: 
interactions with multiple clinicians within a system. Patients may have prescriptions from specialists or 
surgeons and may then be referred back to their primary care physician – or the reverse. An 
inpatient visit may also shift a patient’s medications: it is well documented that when patients are 
admitted to the hospital, their medications may change considerably and new medications may be 
added, further increasing potentially dangerous polypharmacy (30, 31). When clinicians see patients, 
they must assess the patient’s history and current prescriptions through careful medication 
reconciliation (32), determine the appropriateness of the current regimen, and decide whether to 
continue the current medication regimen or change it. As I describe in Study 2, many clinicians may 
be uncomfortable or averse to assuming a new patient’s existing medications if they perceive that the 
regimen is inappropriate or if they are generally unwilling to prescribe certain types of chronic 
medications (such as controlled substances). If clinicians determine that a prescription is 
inappropriate, they may have to discuss tapering down with the patient, an often time-consuming 
and challenging process. Thus, considering patients’ prescriptions from and interactions with 
previous prescribers is an important expansion of the MMIP. 
In sum, I argue that the MMIP should be expanded to include new constructs (nature of the 
patient-clinician relationship, risk management, ethical considerations, and professional roles), and to 
consider two important processes not currently captured within the model: how clinicians make 
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prescribing decisions over time given patients’ evolving risks and benefits, and interactions with 
other prescribers in the system. Including these types of interactions with other prescribers in the 
system more realistically captures decisions clinicians must face when making prescribing decisions 
for new or established patients. An expanded MMIP could help guide interventions aimed at 
reducing polypharmacy and improving the appropriateness of prescribing. In the case of opioid 
prescribing, understanding where and when a patient’s high-dose regimen starts can help identify 
and target areas for improvement.  
Conclusion 
The studies in this dissertation shed light on three aspects of decision-making with respect to 
opioid prescribing, but further research is needed on this critically important public health topic. 
There is little known about patients who have experienced abrupt discontinuation of their opioid 
prescriptions due to clinician choices. Further research is also needed in understanding the 
effectiveness and unintended consequences of new legislation around opioid prescribing, including 
prescription duration limits and policies requiring that clinicians prescribe naloxone to individuals on 
long-term opioid therapy. Given the urgency with which these policies were developed, they may 
have significant shortcomings that should be assessed in order to determine whether patients are 
being harmed during their implementation.  
Given the current public health crisis, clinicians face many complex decisions when 
prescribing opioids in order to maximize safety while treating pain. These complex, nuanced 
decisions likely necessitate several ongoing conversations with patients to discuss an individual’s risk 
and benefit profile with regards to prescription opioids. Reducing the stigma associated with 
discussion and treatment of substance use is likely to improve these conversations for both clinicians 
and their patients. Ensuring that clinicians have adequate training and incentives to manage opioid 
prescribing appropriately will also likely improve quality of care.  
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